[
  {
    "id": "1812232941851799607",
    "type": "single",
    "date": "2024-07-13",
    "year": 2024,
    "tweet_count": 1,
    "is_pearl": false,
    "categories": [
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/gszyqiiw0aa_qmq.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Sat, 13 Jul 2024 21:09:37 GMT",
        "timestamp": 1720919377.0,
        "text": "Today's HFpEF connections: https://t.co/urBOJbs8eO",
        "media": [
          {
            "type": "image",
            "path": "media/images/gszyqiiw0aa_qmq.jpg",
            "remote": false
          }
        ]
      }
    ]
  },
  {
    "id": "1811924664723128702",
    "type": "thread",
    "date": "2024-07-13",
    "year": 2024,
    "tweet_count": 2,
    "is_pearl": false,
    "categories": [
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/gsu_36pxgaapgv9.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/gszyemixiaajide.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Sat, 13 Jul 2024 00:44:38 GMT",
        "timestamp": 1720845878.0,
        "text": "Had fun giving talks on #HFpEF at the @HFSA board review course today. Made some \"HFpEF connections\" puzzles for the audience, in the style of @nytimes connections puzzles. See if you can figure it out! Match groups of 4 clues that are connected. https://t.co/nIK1Cxcd3e",
        "media": [
          {
            "type": "image",
            "path": "media/images/gsu_36pxgaapgv9.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sat, 13 Jul 2024 21:10:37 GMT",
        "timestamp": 1720919437.0,
        "text": "Today's #HFpEF connections: https://t.co/urBOJbsG4m",
        "media": [
          {
            "type": "image",
            "path": "media/images/gszyemixiaajide.jpg",
            "remote": false
          }
        ]
      }
    ]
  },
  {
    "id": "1805272136925487597",
    "type": "single",
    "date": "2024-06-24",
    "year": 2024,
    "tweet_count": 1,
    "is_pearl": false,
    "categories": [
      "General"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Mon, 24 Jun 2024 18:16:11 GMT",
        "timestamp": 1719267371.0,
        "text": "Great thread. Super exciting. But important Q's that the trial won't be able to answer: (1) Once on silencer is TTR stabilizer needed? (2) sequencing of TTR meds? Silencer for dz progression on stabilizers? No data, but impt in terms of getting these $$$ drugs covered for our pts",
        "media": []
      }
    ]
  },
  {
    "id": "1802904221752217701",
    "type": "thread",
    "date": "2024-06-18",
    "year": 2024,
    "tweet_count": 4,
    "is_pearl": false,
    "categories": [
      "Tweetorial",
      "Echo",
      "Diagnosis"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Tue, 18 Jun 2024 03:20:37 GMT",
        "timestamp": 1718695237.0,
        "text": "1/ What was her LVOT VTI? If it's truly LA myopathy, I would expect low SV due to LA failure. But if it LVOT VTI is normal or even elevated would think high output HF. Very young to have HFpEF especially with normal BMI. Overt HF + low H2FPEF score = atypical cause of HF.",
        "media": []
      },
      {
        "date": "Tue, 18 Jun 2024 03:23:05 GMT",
        "timestamp": 1718695385.0,
        "text": "2/ I had a case just like this when I first started my #HFpEF program in 2007. Very similar presentation with elevated LA volume but LVOT VTI was high. She ended up having vitamin B1 deficiency and resolved with diuretics and B1 supplementation",
        "media": []
      },
      {
        "date": "Tue, 18 Jun 2024 03:25:27 GMT",
        "timestamp": 1718695527.0,
        "text": "3/ In high output states, the first chamber to dilate is typically the LA. We see it all the time in pregnancy and in end-stage liver disease, for example. LA typically dilates first. LA strain can be abnormal simply because LA is overloaded (\u2b06\ufe0fLAP)",
        "media": []
      },
      {
        "date": "Tue, 18 Jun 2024 03:29:07 GMT",
        "timestamp": 1718695747.0,
        "text": "4/ But her very low a' velocity does suggest an intrinsic LA problem that is primary. I would do a bike stress echo and see what happens to her LA strain, A, and a' with exercise. Also Holter monitor to look for occult AF/AFL and consider genetic testing",
        "media": []
      }
    ]
  },
  {
    "id": "1776671598977732902",
    "type": "single",
    "date": "2024-04-06",
    "year": 2024,
    "tweet_count": 1,
    "is_pearl": false,
    "categories": [
      "General"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Sat, 06 Apr 2024 19:53:57 GMT",
        "timestamp": 1712447637.0,
        "text": "If you're at the ACC meeting come to the clinical trial deep dive session tomorrow where we will discuss RELIEVE-HF vs REDUCE LAP-HF II. I'll try to post my slides here after my talk.",
        "media": []
      }
    ]
  },
  {
    "id": "1730301780280361141",
    "type": "single",
    "date": "2023-11-30",
    "year": 2023,
    "tweet_count": 1,
    "is_pearl": false,
    "categories": [
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/ganes9nwoaafsuu.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Thu, 30 Nov 2023 23:44:05 GMT",
        "timestamp": 1701405845.0,
        "text": "I'm currently pre-eating pizza at the airport in preparation for KC steakhouse dinner #vegetarian",
        "media": [
          {
            "type": "image",
            "path": "media/images/ganes9nwoaafsuu.jpg",
            "remote": false
          }
        ]
      }
    ]
  },
  {
    "id": "1717828390743380396",
    "type": "thread",
    "date": "2023-10-27",
    "year": 2023,
    "tweet_count": 2,
    "is_pearl": false,
    "categories": [
      "General"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Fri, 27 Oct 2023 08:59:38 GMT",
        "timestamp": 1698411578.0,
        "text": "LAA thrombus may be calcified and resistant to dissolving w/anticoag. Does it look calcified on TEE? Are you trying to cardiovert to see if being in NSR improves symptoms? It's possible that the LA fxn will be no better in NSR given chronic AF plus amyloid (=poor LA mechanics).",
        "media": []
      },
      {
        "date": "Fri, 27 Oct 2023 09:05:12 GMT",
        "timestamp": 1698411912.0,
        "text": "What's the LVOT VTI and HR? Is the pt on an AV nodal blocker? Stroke volume is usually low and fixed in cardiac amyloid so HR ideally 80s at rest and HR ideally \u2b06\ufe0fapprop with exertion. If BP low could see if midodrine \u2b06\ufe0fSV. Is the pt anemic+iron deficient? If so would do IV iron.",
        "media": []
      }
    ]
  },
  {
    "id": "1695076640508842135",
    "type": "thread",
    "date": "2023-08-25",
    "year": 2023,
    "tweet_count": 2,
    "is_pearl": false,
    "categories": [
      "Treatment"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Fri, 25 Aug 2023 14:12:18 GMT",
        "timestamp": 1692987138.0,
        "text": "Yes, already part of the algorithm :) ... https://t.co/sRvYStGdVW but now we can elevate it for sure! A great result for our patients. As I like to say, \"The 2020s is the decade for HFpEF therapeutics\"... finally!",
        "media": []
      },
      {
        "date": "Fri, 25 Aug 2023 17:33:54 GMT",
        "timestamp": 1692999234.0,
        "text": "Love it! #SQUAD. I definitely think we need to consider GLP1-RA trials in people with HFpEF, BMI<30, and evidence of significant visceral adiposity...",
        "media": []
      }
    ]
  },
  {
    "id": "1662089509729705984",
    "type": "thread",
    "date": "2023-05-26",
    "year": 2023,
    "tweet_count": 3,
    "is_pearl": false,
    "categories": [
      "Echo",
      "Hemodynamics",
      "Treatment",
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/fxdtmgvxgaqmwvw.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Fri, 26 May 2023 13:33:13 GMT",
        "timestamp": 1685122393.0,
        "text": "Looks like NF type 1 to me. I had a pt with NF1 who was initially dx\u2019d as PH-HFpEF due to \u2b06\ufe0fPCWP & \u2b06\ufe0fPVR but echo looked like PAH. Repeat cath after diuresis showed PAH. She didn\u2019t have ILD which can occur w/NF1. We suspected a pulmonary vasculopathy possibly involving pulm veins",
        "media": [
          {
            "type": "image",
            "path": "media/images/fxdtmgvxgaqmwvw.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 26 May 2023 13:36:23 GMT",
        "timestamp": 1685122583.0,
        "text": "Treatment was very challenging. Pts with NF1 can also get HCM and other complications assoc with left heart disease (eg renovascular HTN, diseases of the aorta, etc) which could \u27a1\ufe0fHFpEF. Can we see the echo? Rest of the hemodynamic tracings? Was DPG\u2b06\ufe0f? Did you check PCWP sat?",
        "media": []
      },
      {
        "date": "Fri, 26 May 2023 13:38:42 GMT",
        "timestamp": 1685122722.0,
        "text": "Looking forward to finding out what the patient had and how they were treated! Here is the ref for the image above. I found this review to be very helpful when I first saw my patient with PH due to NF1. https://err.ersjournals.com/content/27/149/180053",
        "media": []
      }
    ]
  },
  {
    "id": "1662090305896628225",
    "type": "thread",
    "date": "2023-05-26",
    "year": 2023,
    "tweet_count": 2,
    "is_pearl": false,
    "categories": [
      "Echo",
      "Hemodynamics",
      "Treatment"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Fri, 26 May 2023 13:36:23 GMT",
        "timestamp": 1685122583.0,
        "text": "Treatment was very challenging. Pts with NF1 can also get HCM and other complications assoc with left heart disease (eg renovascular HTN, diseases of the aorta, etc) which could \u27a1\ufe0fHFpEF. Can we see the echo? Rest of the hemodynamic tracings? Was DPG\u2b06\ufe0f? Did you check PCWP sat?",
        "media": []
      },
      {
        "date": "Fri, 26 May 2023 13:38:42 GMT",
        "timestamp": 1685122722.0,
        "text": "Looking forward to finding out what the patient had and how they were treated! Here is the ref for the image above. I found this review to be very helpful when I first saw my patient with PH due to NF1. https://err.ersjournals.com/content/27/149/180053",
        "media": []
      }
    ]
  },
  {
    "id": "1650436742250364929",
    "type": "thread",
    "date": "2023-04-24",
    "year": 2023,
    "tweet_count": 7,
    "is_pearl": false,
    "categories": [
      "Treatment",
      "Diagnosis"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Mon, 24 Apr 2023 09:49:17 GMT",
        "timestamp": 1682344157.0,
        "text": "Regarding metolazone, it tends to be very potent, can cause lots of electrolyte abnormalities, so I will usually try HCTZ first, even when GFR is low",
        "media": []
      },
      {
        "date": "Mon, 24 Apr 2023 09:48:06 GMT",
        "timestamp": 1682344086.0,
        "text": "And then this paper came out showing possibly worse electrolyte abnormalities with chlorthalidone: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2760777 and this RCT came out showing no efficacy difference between the 2 medications in terms of outcomes: https://www.nejm.org/doi/10.1056/NEJMoa2212270",
        "media": []
      },
      {
        "date": "Mon, 24 Apr 2023 09:45:16 GMT",
        "timestamp": 1682343916.0,
        "text": "I used to use chlorthalidone over HCTZ b/c of the trial data showing chlorthalidone more potent at lowering BP than HCTZ without differences in side effects. However, in clinical practice my experience is that HCTZ has \u2b07\ufe0fside effects and easier for pts to obtain at their pharmacy",
        "media": []
      },
      {
        "date": "Mon, 24 Apr 2023 09:53:31 GMT",
        "timestamp": 1682344411.0,
        "text": "Clinically I'm more focused on congestion than BNP or NTproBNP. If the patient has evidence of congestion, I use SGLT2i. If the pt doesn't have overt congestion, I'm more selective/careful about SGLT2i use unless they have an elevated NTproBNP or evidence of CKD.",
        "media": []
      },
      {
        "date": "Mon, 24 Apr 2023 09:57:58 GMT",
        "timestamp": 1682344678.0,
        "text": "In the PRESERVED-HF trial, which showed that dapagliflozin increased KCCQ and 6MWT compared to placebo, the NTproBNP cut-off for exclusion was lower (<225 pg/ml). Also, subgroup analyses of SGLT2i HF RCTs haven't found interaction between baseline NTproBNP and efficacy",
        "media": []
      },
      {
        "date": "Mon, 24 Apr 2023 10:05:49 GMT",
        "timestamp": 1682345149.0,
        "text": "The H2FPEF score should only be used in pts with symptoms of dyspnea or exercise intolerance (i.e., not all older pts with obesity and AF). And H2FpEF, like any score or test (even NTproBNP) should not be used in isolation without interpreting the rest of the clinical data.",
        "media": []
      },
      {
        "date": "Mon, 24 Apr 2023 10:09:01 GMT",
        "timestamp": 1682345341.0,
        "text": "HFpEF RCTs have typically relied on \u2b06\ufe0fNTproBNP levels as inclusion criteria, which does not necessarily mean the patient is congested. Main point is that the H2FPEF score can raise awareness of HFpEF and is useful as 1 test to help get to the correct diagnosis in breathless pts.",
        "media": []
      }
    ]
  },
  {
    "id": "1649588099608117248",
    "type": "thread",
    "date": "2023-04-22",
    "year": 2023,
    "tweet_count": 9,
    "is_pearl": false,
    "categories": [
      "Tweetorial",
      "Echo",
      "Hemodynamics",
      "Treatment",
      "Diagnosis",
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/fusbistamaaljlz.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/fusdgibakaabefm.png",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Sat, 22 Apr 2023 01:37:05 GMT",
        "timestamp": 1682141825.0,
        "text": "1/ How to use the H2FPEF score (https://pmc.ncbi.nlm.nih.gov/articles/PMC6202181/ to assist with the diagnosis of #HFpEF.",
        "media": [
          {
            "type": "image",
            "path": "media/images/fusbistamaaljlz.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sat, 22 Apr 2023 01:37:06 GMT",
        "timestamp": 1682141826.0,
        "text": "2/ First, H2FPEF score should only be used in pts w/dyspnea or exercise intolerance in whom the diagnosis of HFpEF vs non-cardiac dyspnea is unclear. If unsure about presence of symptoms: Do a 6MWT in the clinic to more objectively determine if exercise intolerance is present.",
        "media": []
      },
      {
        "date": "Sat, 22 Apr 2023 01:37:08 GMT",
        "timestamp": 1682141828.0,
        "text": "3/ Score 5+: very high likelihood of HFpEF; score 0-1: very unlikely HFpEF; score 2-4: need to do provocative (exercise) testing to make the diagnosis",
        "media": []
      },
      {
        "date": "Sat, 22 Apr 2023 01:37:09 GMT",
        "timestamp": 1682141829.0,
        "text": "4/ Tips on scoring #1: All diuretics (except for SGLT2i) count as anti-HTN meds. Any med that can be used as anti-HTN counts as anti-HTN. Combo anti-HTN meds? Add up # of component meds (e.g., losartan/HCTZ combo pill = 2 anti-HTN meds).",
        "media": []
      },
      {
        "date": "Sat, 22 Apr 2023 01:37:10 GMT",
        "timestamp": 1682141830.0,
        "text": "5/ Tips on scoring #2: List of anti-HTN meds:",
        "media": [
          {
            "type": "image",
            "path": "media/images/fusdgibakaabefm.png",
            "remote": false
          }
        ]
      },
      {
        "date": "Sat, 22 Apr 2023 01:37:12 GMT",
        "timestamp": 1682141832.0,
        "text": "6/ Tips on scoring #3: AF includes any history of AF or atrial flutter (either paroxysmal or persistent). Currently in AF not needed. PH: If PA systolic pressure not measurable on echo, score for PA pressure = zero points.",
        "media": []
      },
      {
        "date": "Sat, 22 Apr 2023 01:37:13 GMT",
        "timestamp": 1682141833.0,
        "text": "7/ A low H2FPEF score does not rule out HFpEF if there is other evidence of HF such as \u2b06\ufe0fBNP or \u2b06\ufe0fNTproBNP, CXR evidence of HF, \u2b06\ufe0fLV filling pressures on invasive hemodynamic testing, prior HF hospitalization, etc).",
        "media": []
      },
      {
        "date": "Sat, 22 Apr 2023 01:37:13 GMT",
        "timestamp": 1682141833.0,
        "text": "8/ A low H2FPEF score in the presence of overt objective evidence of HF in a patient with LVEF \u226550% is indicative of a possible HFpEF masquerader or atypical etiology of HFpEF.",
        "media": []
      },
      {
        "date": "Sat, 22 Apr 2023 01:37:14 GMT",
        "timestamp": 1682141834.0,
        "text": "9/ Like any score, H2FPEF not perfect, so proceed to definitive testing, carefully examine echo, perform invasive hemodynamics, consider CPET if something isn't adding up when evaluating your patients.",
        "media": []
      }
    ]
  },
  {
    "id": "1649734238193811458",
    "type": "thread",
    "date": "2023-04-22",
    "year": 2023,
    "tweet_count": 2,
    "is_pearl": false,
    "categories": [
      "General"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Sat, 22 Apr 2023 11:13:17 GMT",
        "timestamp": 1682176397.0,
        "text": "The original paper said 2-5 but score of 5 \u27a1\ufe0f>80% prob of HFpEF. In the validation cohort in the paper, LR+ was 4.8 at a cut-off score of 4. If pre-test prob = 30%, then even a score of 4 gives post-test probability of 67%, and it'll be higher for a score of 5.",
        "media": []
      },
      {
        "date": "Sat, 22 Apr 2023 11:17:47 GMT",
        "timestamp": 1682176667.0,
        "text": "So in most cases, score=5 means very likely HFpEF. However, if pre-test probability \u226420% (meaning you think HFpEF pretty unlikely), then a score of 5 should prompt further testing.",
        "media": []
      }
    ]
  },
  {
    "id": "1649724001852203010",
    "type": "thread",
    "date": "2023-04-22",
    "year": 2023,
    "tweet_count": 2,
    "is_pearl": false,
    "categories": [
      "Treatment",
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/fuue41awiaqn8ga.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Sat, 22 Apr 2023 10:37:07 GMT",
        "timestamp": 1682174227.0,
        "text": "Fantastic thread. I would add anti-obesity treatment (GLP1RA/bariatric surg)",
        "media": []
      },
      {
        "date": "Sat, 22 Apr 2023 11:05:05 GMT",
        "timestamp": 1682175905.0,
        "text": "It's in there\ud83d\ude42...Step 5 (comorbidity management). I've definitely had some dramatic cases of complete resolution of HFpEF after bariatric surgery and also w/GLP1-RA. Example below. I'm very hopeful that we'll see beneficial effects in STEP-HFpEF and SUMMIT GLP1-RA HFpEF RCTs!",
        "media": [
          {
            "type": "image",
            "path": "media/images/fuue41awiaqn8ga.jpg",
            "remote": false
          }
        ]
      }
    ]
  },
  {
    "id": "1649744475151843334",
    "type": "single",
    "date": "2023-04-22",
    "year": 2023,
    "tweet_count": 1,
    "is_pearl": false,
    "categories": [
      "Hemodynamics",
      "Diagnosis"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Sat, 22 Apr 2023 11:58:28 GMT",
        "timestamp": 1682179108.0,
        "text": "There is a gold standard diagnostic test for HFpEF: invasive exercise hemodynamics (right heart catheterization). PCWP \u226515 mmHg at rest, PCWP \u226525 mmHg with supine exercise, or PCWP/CO slope >2.0 with upright exercise in a patient with HF symptoms and LVEF \u226550%.",
        "media": []
      }
    ]
  },
  {
    "id": "1649345816794914817",
    "type": "thread",
    "date": "2023-04-21",
    "year": 2023,
    "tweet_count": 27,
    "is_pearl": false,
    "categories": [
      "Tweetorial",
      "Treatment",
      "Diagnosis",
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/fuoiz6iwwaepe0o.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/fuoi3-lxsaaxctp.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/fuojdyhxgaalrxj.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Fri, 21 Apr 2023 09:34:20 GMT",
        "timestamp": 1682084060.0,
        "text": "1/ #HFpEF treatment algorithm #tweetorial. This is the algorithm I currently use to treat HFpEF based on evidence we have thus far and my anecdotal experience treating patients over the past 16 years in the @NMCardioVasc HFpEF Clinic.",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:21 GMT",
        "timestamp": 1682084061.0,
        "text": "2/ This treatment algorithm was recently published in @JACCJournals with my friends and co-authors Barry Borlaug, @KSharmaMD, and @JenHoCardiology (who provided great feedback!). https://www.jacc.org/doi/abs/10.1016/j.jacc.2023.01.049",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:21 GMT",
        "timestamp": 1682084061.0,
        "text": "3/ Step 1: Start by confirming the #HFpEF diagnosis. In equivocal cases, remember to use provocative testing, preferably exercise testing! https://pmc.ncbi.nlm.nih.gov/articles/PMC9542249/",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:22 GMT",
        "timestamp": 1682084062.0,
        "text": "4/ Step 2: Once the diagnosis of HFpEF is made based on elevated LV filling pressures at rest or with exercise in the setting of an LVEF \u226550%, first evaluate for masqueraders\u2026",
        "media": [
          {
            "type": "image",
            "path": "media/images/fuoiz6iwwaepe0o.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:22 GMT",
        "timestamp": 1682084062.0,
        "text": "5/ \u2026if you take care of patients with HFpEF, you need to know your zebras!",
        "media": [
          {
            "type": "image",
            "path": "media/images/fuoi3-lxsaaxctp.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:23 GMT",
        "timestamp": 1682084063.0,
        "text": "6/ Step 3: Start with an SGLT2i in all pts but use with caution in pts with exercise-induced LA hypertension (EILAH) because they have normal filling pressures at rest. See our recent paper on EILAH in @JACCJournals: https://t.co/bPqRVuQx3q",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:23 GMT",
        "timestamp": 1682084063.0,
        "text": "7/ Step 4: Is volume overload present? If so, start diuretics, with preferential up-front use of an MRA (e.g., spironolactone) and loop diuretics as needed (but minimize loop diuretic dose once euvolemic)",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:24 GMT",
        "timestamp": 1682084064.0,
        "text": "8/ Step 5: Treat comorbidities\u2026",
        "media": [
          {
            "type": "image",
            "path": "media/images/fuojdyhxgaalrxj.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:24 GMT",
        "timestamp": 1682084064.0,
        "text": "9/ Step 6: Start ARNI (sacubitril/valsartan) if not yet started for high BP if the patient is (1) still symptomatic, (2) LVEF <55-60% or frequent HF hospitalizations or +residual congestion, and (3) systolic BP >110 mmHg, and up-titrate as tolerated",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:24 GMT",
        "timestamp": 1682084064.0,
        "text": "10/ Step 7: Ask 6 key questions in all patients:\n(1) Is the pt on an SGLT2i? If not, why not?\n(2) Is the pt on an MRA? If not, why not?\n(3) Is the pt on an ARNI? If not, why not?\n(4) Is the patient on K+? If yes, replace with (or up-titrate) MRA if possible",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:25 GMT",
        "timestamp": 1682084065.0,
        "text": "11/ Step 7 (continued):\n(5) Is the patient on a nitrate or pulmonary vasodilator? Discontinue if possible\n(6) Is the patient on a beta-blocker? Wean off unless using for AF, angina, or MI, or other non-HFpEF indication",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:25 GMT",
        "timestamp": 1682084065.0,
        "text": "12/ Step 8a: Implement HF education in all patients (daily weights, BP, and HR; establish \u201cdry weight\u201d for volume overloaded pts to guide diuretic dosing [esp loop diuretics])",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:26 GMT",
        "timestamp": 1682084066.0,
        "text": "13/ Step 8b: Educate pts on an exercise training regimen that combines aerobic training + resistance training (maintaining muscle mass and reducing risk for worsening frailty is critical!). Phase 3 cardiac rehab or Rx pulmonary rehab in pts with concomitant pulmonary disease",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:26 GMT",
        "timestamp": 1682084066.0,
        "text": "14/ Step 9: For persistent symptoms and/or HF hospitalizations \u27a1\ufe0f HF clinic referral, reevaluate for HFpEF masqueraders, check for worsening comorbidities, if persistent fluid overload Rx HCTZ, use implantable PA monitoring, and evaluate for chronotropic incompetence",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:26 GMT",
        "timestamp": 1682084066.0,
        "text": "15/ Step 10: ENROLL IN A HFpEF CLINICAL TRIAL!",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:27 GMT",
        "timestamp": 1682084067.0,
        "text": "16/ Additional tip #1: In patients with persistent fluid overload on SGLT2i, MRA, and loop diuretic, avoid metolazone! Low-dose HCTZ typically works because of the benefit of sequential nephron blockade...",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:27 GMT",
        "timestamp": 1682084067.0,
        "text": "17/ ...The distal convoluted tubule is amped up if already on SGLT2i, MRA, and loop diuretic, so just a little bit of HCTZ (e.g., 12.5 mg qd) can result in significant diuresis. What if eGFR is very low? No problem, if still making urine, HCTZ will still usually work in HF pts.",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:27 GMT",
        "timestamp": 1682084067.0,
        "text": "18/ Additional tip #2: Which exercise training regimen do you prescribe? I try to mimic what\u2019s been done in trials of exercise in HFpEF patients\u2026 https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.122.010161",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:28 GMT",
        "timestamp": 1682084068.0,
        "text": "19/ Additional tip #4: Pathophys often changes in HFpEF pts as they have events (e.g., hospitalization; changes in lifestyle, diet, environment; new meds started for other conditions; new-onset comorbidities or cardiac conditions). Don\u2019t get complacent when caring for HFpEF pts!",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:28 GMT",
        "timestamp": 1682084068.0,
        "text": "20/ Additional tip #5: When caring for HFpEF pts, we often become the coordinator of care \u27a1\ufe0f need to treat the WHOLE patient in order to make them feel better. Provide a multi-disciplinary Rx plan.",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:29 GMT",
        "timestamp": 1682084069.0,
        "text": "21/ Additional tip #6: Avoid polypharmacy, use combo meds when possible (many are generic), and watch out for adverse effects of non-cardiac medications that may exacerbate HFpEF.",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:29 GMT",
        "timestamp": 1682084069.0,
        "text": "22/ Finally\u2026 there are many patients with HFpEF that need our help. Please consider starting a dedicated HFpEF program at your institution if you don\u2019t have one already. This paper explains how to do it \ud83d\ude0a\u2026 https://t.co/dDefoC5AGo",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:30 GMT",
        "timestamp": 1682084070.0,
        "text": "23/ Caveats (the fine print): SGLT2i should be considered in all patients except those with type 1 diabetes, orthostatic hypotension, eGFR <20-25, or very frequent yeast infections (or history of severe GU infections).",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:30 GMT",
        "timestamp": 1682084070.0,
        "text": "24/ Caveats (cont\u2019d): Yeast infections are readily treatable, usually not a reason to permanently stop SGLT2i. Instruct pts to hold SGLT2i therapy for a few days on \u201csick days\u201d (GI illness, dehydration, active infections). High HgbA1c not a contraindication to SGLT2i.",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:30 GMT",
        "timestamp": 1682084070.0,
        "text": "25/ Caveats (cont\u2019d): MRA should be considered in all pts except those with K+ >5.0 or eGFR <30. Replace K+ supplementation with MRA whenever possible. Re-check K+ and renal function 1 week and 1 month after initiation, and q3-6 months thereafter.",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:31 GMT",
        "timestamp": 1682084071.0,
        "text": "26/ Caveats (cont\u2019d): ARNI most effective if EF <55-60% or frequent HF hosp (congested phenotype); avoid in pts with history of angioedema, low BP, orthostatic hypotension, restrictive cardiomyopathy, pulmonary arterial hypertension, constrictive pericarditis, cardiac amyloidosis",
        "media": []
      },
      {
        "date": "Fri, 21 Apr 2023 09:34:31 GMT",
        "timestamp": 1682084071.0,
        "text": "27/ Caveats (cont\u2019d): AF patients often have low stroke volume and inability to augment stroke volume during exertion due to LA dysfunction. Avoid excessive rate control in these patients.",
        "media": []
      }
    ]
  },
  {
    "id": "1644224088821448704",
    "type": "thread",
    "date": "2023-04-07",
    "year": 2023,
    "tweet_count": 30,
    "is_pearl": false,
    "categories": [
      "Tweetorial",
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/ftfrxo9xwaqnd9i.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/ftfrxo9xwaqnd9i.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/ftftddexsaarag8.png",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/ftf0_lgx0aeuzqy.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/ftf0xz3xoai9xms.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/ftf2ef3wcamklub.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/ftf3ms_xwaed_xo.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Fri, 07 Apr 2023 06:22:25 GMT",
        "timestamp": 1680862945.0,
        "text": "1/ Grant-writing tips. This #tweetorial mainly applies to @NIH grants (particularly R01s) but some stuff may be applicable to other types of grants and funding agencies. Based on my experience writing grants for 20 yrs +lots of cringe-worthy missteps and rejections along the way!",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:26 GMT",
        "timestamp": 1680862946.0,
        "text": "2/ Where do you begin? Part 1: pick scientific topics that you love thinking about and reading about. Start building a story. Publish 4-5 papers on your topic (1st or last author) to establish yourself. Make sure you're senior author on a few papers (shows independence)",
        "media": [
          {
            "type": "image",
            "path": "media/images/ftfrxo9xwaqnd9i.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:26 GMT",
        "timestamp": 1680862946.0,
        "text": "3/ Where do you begin? Part 2: Think big, come up with a \u201czero-to-one\u201d idea. Don't be incremental. If you had $100M to solve your scientific problem, what would you do? Write down all your ideas \u27a1\ufe0f narrow idea to $10M project \u27a1\ufe0f narrow further to a $2M ($500K x 4 yrs for an R01).",
        "media": [
          {
            "type": "image",
            "path": "media/images/ftfrxo9xwaqnd9i.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:26 GMT",
        "timestamp": 1680862946.0,
        "text": "4/ Where do you begin? Part 3: Once you narrow down your ideas, write the aims. Not the whole aims page, just 3 aims with no background. Write ~10 sets of aims based on your ideas.  Show mentors, colleagues, experts \u27a1\ufe0f narrow down to 1-2 sets of aims \u27a1\ufe0f develop into final aims.",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:27 GMT",
        "timestamp": 1680862947.0,
        "text": "5/ Write your specific aims page and get right to the point. Don\u2019t spend a paragraph making general statements about the field you\u2019re studying. Quickly get to critical unmet need and potential solutions. Briefly state your relevant prior work, prelim data summary, and innovation.",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:27 GMT",
        "timestamp": 1680862947.0,
        "text": "6/ Consider adding 1 sentence explaining why you and the team you've assembled is uniquely equipped to do the proposed work.",
        "media": [
          {
            "type": "image",
            "path": "media/images/ftftddexsaarag8.png",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:28 GMT",
        "timestamp": 1680862948.0,
        "text": "7/ List your overarching aim and then ~3 specific aims. Be as detailed as possible. The reviewer should be able to clearly visualize the study design based on the aims. List your hypotheses for each aim. Avoid making the aims dependent on each other!",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:28 GMT",
        "timestamp": 1680862948.0,
        "text": "8/ Dependent aims: e.g., the ability to do Aim #2 depends on the success of Aim #1. Ideally aims should be different ways of tackling your scientific problem, and therefore a \"win-win\".",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:28 GMT",
        "timestamp": 1680862948.0,
        "text": "9/ What does a \u201cwin-win\u201d approach to specific aims mean? Ideally your specific aims will be set up so that even if your hypothesis is wrong, your study will have a major impact on your field of research.",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:29 GMT",
        "timestamp": 1680862949.0,
        "text": "10/ Examples: (1) even if your hypotheses are wrong, your project will create a valuable resource for the field; (2) you\u2019re conducting a definitive study so even proving your hypothesis wrong will be very helpful for the field to move in a different direction of research.",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:29 GMT",
        "timestamp": 1680862949.0,
        "text": "11/ Use \u201cparallel writing\u201d structure throughout your aims page and the rest of your grant. Let\u2019s say your 3 aims are on genomic, proteomic, and metabolomic interrogation of a disease. Throughout your aims page (background, prelim data, aims). Keep this order and don\u2019t deviate.",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:29 GMT",
        "timestamp": 1680862949.0,
        "text": "12/ Use this parallel writing structure in each section of the grant (significance, innovation, prelim data, approach, etc) don\u2019t deviate. In the example above, each section would start with genomic, then proteomic, then metabolomic. Same in figures and tables.",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:30 GMT",
        "timestamp": 1680862950.0,
        "text": "13/ End your aims page with: \u201cThere is a critical unmet need to use novel strategies to solve <SCIENTIFIC PROBLEM>. We have <LIST EXPERTISE, PRIOR ACCOMPLISHMENTS> and are therefore uniquely suited to lead the proposed studies which will have a major impact on <SCIENTIFIC FIELD>.",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:30 GMT",
        "timestamp": 1680862950.0,
        "text": "14/ Knowing what reviewers are looking for in the 5 review criteria (significance, investigator, innovation, approach, environment) is very helpful. I will outline some tips for each below.",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:30 GMT",
        "timestamp": 1680862950.0,
        "text": "15/ Significance is not \u201cbackground\u201d on your topic. Need to answer a very specific Q: If you successfully complete your aims, will your project have major impact on the field? Is what you\u2019re studying a big problem? What are the unmet needs? Gaps of prior studies + your solutions",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:31 GMT",
        "timestamp": 1680862951.0,
        "text": "16/ Investigator, Part 1: Make sure all biosketches (yours, co-investigators, consultants, etc) are up to date, have tailored personal statements relevant to your grant, and all look the same. I edit and reformat all personal statements in my grants to make them look uniform.",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:31 GMT",
        "timestamp": 1680862951.0,
        "text": "17/ Investigator, Part 2: You want to make your investigative team shine, so the biosketches need to be clear, informative, and relevant. Include relevant letters of support, and make sure your letter writers highlight your great work and accomplishments.",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:32 GMT",
        "timestamp": 1680862952.0,
        "text": "18/ Investigator, Part 3: Insert a brief section in your grant on qualifications of the investigative team + why you're uniquely suited to do the proposed work. Add citations that back up your statements. Highlight prior collaborative publications (here and in your biosketches).",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:32 GMT",
        "timestamp": 1680862952.0,
        "text": "19/ Innovation: Most grants are not super innovative, and that\u2019s okay. Even if you think what you\u2019re doing is innovative, the reviewers will probably not. Keep it short. It could be the team that you\u2019ve assembled, the resource you\u2019re using, and/or the approach. Don't oversell it.",
        "media": [
          {
            "type": "image",
            "path": "media/images/ftf0_lgx0aeuzqy.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:33 GMT",
        "timestamp": 1680862953.0,
        "text": "20/ Approach #1: Provide details of the unique resource(s) you're using for your studies (e.g., about parent study if proposing an ancillary study; explanation/rationale for model systems you're using for experiments). Provide prelim data. Remember parallel writing structure.",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:33 GMT",
        "timestamp": 1680862953.0,
        "text": "21/ Approach #2: After intro and prelim data, create a new subsection for each aim. Write out each aim and its associated hypothesis again (user friendly for reviewers). Next, provide very brief rationale and prelim data here if it flows better. But quickly get to your methods.",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:33 GMT",
        "timestamp": 1680862953.0,
        "text": "22/ Approach #3: Power calculations, statistical analysis. Don\u2019t skimp on these. Most grant review panels are filled with reviewers with deep expertise in statistics. Lack of sample size calculations or insufficient stats details = easy for reviewer to trash a grant.",
        "media": [
          {
            "type": "image",
            "path": "media/images/ftf0xz3xoai9xms.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:34 GMT",
        "timestamp": 1680862954.0,
        "text": "23/ Approach #4: Include an alternative approaches section; try to anticipate critiques and discuss how you will get around them.",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:34 GMT",
        "timestamp": 1680862954.0,
        "text": "24/ Environment #1: Use the resources and facilities part of your grant to highlight your amazing environment. Tailor this section to your grant! Personalize it and try not to include a bunch of irrelevant information.",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:34 GMT",
        "timestamp": 1680862954.0,
        "text": "25/ Environment #2: You need to convince reviewers that your environment (and that of your collaborators) is ideal and fully equipped to help you succeed. Provide letters of support (approval) for any resources you are using for your project that do not belong to you.",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:22:34 GMT",
        "timestamp": 1680862954.0,
        "text": "26/ Miscellaneous tip #1: For the specific aims page and research strategy, make sure you use 0.5\u201d borders, and 11-point Arial or Helvetica font. This is what the reviewers are expecting and what they\u2019re used to. Don\u2019t deviate.",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:31:49 GMT",
        "timestamp": 1680863509.0,
        "text": "27/ Miscellaneous #2: Make sure you fill up the entire allotted space for the grant. For an R01 = 1 page for specific aims + 12 pages for research strategy. If you can't fill the entire 13 pages either your project isn't important or you haven't included enough detail or both.",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:31:49 GMT",
        "timestamp": 1680863509.0,
        "text": "28/ Miscellaneous #3: Make your grant look pristine. Uniform formatting throughout. Don\u2019t use excessively small fonts in tables/figures. In Word, go to Format > Paragraph. Set spacing as shown below. Use consistent lettering/numbering system for outlining sections of your grant.",
        "media": [
          {
            "type": "image",
            "path": "media/images/ftf2ef3wcamklub.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 07 Apr 2023 06:31:49 GMT",
        "timestamp": 1680863509.0,
        "text": "29/ Miscellaneous #4: Figures. Unless it's a photo, use vector format. Create your figure (eg, graph, diagram) and save as PDF format and then insert it into the document as a PDF. This will preserve the vector format so the figures are not pixelated (raster format, e.g., JPEG).",
        "media": []
      },
      {
        "date": "Fri, 07 Apr 2023 06:31:50 GMT",
        "timestamp": 1680863510.0,
        "text": "I use a Mac and make my figures in PowerPoint. Then I copy the entire figure and Edit > Paste Special\u2026 and paste it as a PDF. I then copy that PDF version of the figure and paste it into Word. See comparison below, the vector format is clean; raster format is grainy.",
        "media": [
          {
            "type": "image",
            "path": "media/images/ftf3ms_xwaed_xo.jpg",
            "remote": false
          }
        ]
      }
    ]
  },
  {
    "id": "1623369095642025998",
    "type": "single",
    "date": "2023-02-08",
    "year": 2023,
    "tweet_count": 1,
    "is_pearl": false,
    "categories": [
      "General"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Wed, 08 Feb 2023 17:12:07 GMT",
        "timestamp": 1675894327.0,
        "text": "Thank you @AbbateAntonio and @ChrisKramerMD, @AmitRPatelMD, and Jonathan Lindner for hosting me for the John P. DiMarco, MD Lectureship. Great visiting @CardioUva! Had a great time at dinner with faculty and fellows last night and meeting with the cardiology fellows today.",
        "media": []
      }
    ]
  },
  {
    "id": "1618806206881218560",
    "type": "single",
    "date": "2023-01-27",
    "year": 2023,
    "tweet_count": 1,
    "is_pearl": false,
    "categories": [
      "Treatment"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Fri, 27 Jan 2023 03:00:50 GMT",
        "timestamp": 1674806450.0,
        "text": "Thanks @CvUnmc for inviting me to give a talk on #HFpEF! I\u2019m really hoping that the 2020s is the decade of HFpEF. Started out strong with #SGLT2i, hopefully we will see the momentum continue with additional advances to improve the lives of our HFpEF patients.",
        "media": []
      }
    ]
  },
  {
    "id": "1602832104311738369",
    "type": "thread",
    "date": "2022-12-14",
    "year": 2022,
    "tweet_count": 3,
    "is_pearl": false,
    "categories": [
      "Echo",
      "Diagnosis",
      "Video"
    ],
    "media": [
      {
        "type": "video",
        "path": "media/videos/af38iguvog5ug054.mp4",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/fj9n2dgwqaae98n.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Wed, 14 Dec 2022 01:05:27 GMT",
        "timestamp": 1670997927.0,
        "text": "Reading in the echo lab today... a woman in her 70s with HTN, diabetes, hyperlipidemia presents to ER with shortness of breath. Echo below. IVC was small and collapses >50% consistent with normal RA pressure (0-5 mmHg). What's the diagnosis?",
        "media": [
          {
            "type": "video",
            "path": "media/videos/af38iguvog5ug054.mp4",
            "remote": false
          }
        ]
      },
      {
        "date": "Wed, 14 Dec 2022 19:45:47 GMT",
        "timestamp": 1671065147.0,
        "text": "The echo shows prominent diastolic septal flattening but minimal systolic septal flattening. Normally we see this with RV volume overload, but est. RA pressure was normal. So we need to think of other mechanisms that would cause diastolic septal flattening...",
        "media": []
      },
      {
        "date": "Wed, 14 Dec 2022 19:46:24 GMT",
        "timestamp": 1671065184.0,
        "text": "Mitral E velocity was 0.5 cm/s and E/A ratio was 0.6. So the left heart was underfilled. Here is the answer...",
        "media": [
          {
            "type": "image",
            "path": "media/images/fj9n2dgwqaae98n.jpg",
            "remote": false
          }
        ]
      }
    ]
  },
  {
    "id": "1511889957253697543",
    "type": "thread",
    "date": "2022-04-07",
    "year": 2022,
    "tweet_count": 3,
    "is_pearl": false,
    "categories": [
      "Tweetorial",
      "Hemodynamics"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Thu, 07 Apr 2022 02:13:50 GMT",
        "timestamp": 1649312030.0,
        "text": "We see this all the time in high output states. LA is usually the first chamber to dilate in high output states. Think of pregnancy where we often see it by the 3rd trimester. I always measure all 4 chambers in pts with liver disease because often multiple chambers are enlarged",
        "media": []
      },
      {
        "date": "Thu, 07 Apr 2022 02:23:54 GMT",
        "timestamp": 1649312634.0,
        "text": "1/ As NAFLD becomes the leading cause of end-stage liver disease and with the older age of liver transplant recipients we are seeing more cases of elevated PCWP pre-transplant. Pts often have risk factors for diastolic dysfunction but would normally be grade I DD.",
        "media": []
      },
      {
        "date": "Thu, 07 Apr 2022 02:24:26 GMT",
        "timestamp": 1649312666.0,
        "text": "2/ But with high flow coupled with DD and LA stiffening, PCWP goes up. In fact, lack of LA dilation in response to \u2b06\ufe0fCO may be a sign of LA stiffening in ESLD and that\u2019s why smaller LA volumes had worse outcomes. That or pulmonary vascular disease with LA underfilling.",
        "media": []
      }
    ]
  },
  {
    "id": "1511879739354628105",
    "type": "thread",
    "date": "2022-04-07",
    "year": 2022,
    "tweet_count": 3,
    "is_pearl": false,
    "categories": [
      "Tweetorial",
      "Hemodynamics"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Thu, 07 Apr 2022 02:13:50 GMT",
        "timestamp": 1649312030.0,
        "text": "We see this all the time in high output states. LA is usually the first chamber to dilate in high output states. Think of pregnancy where we often see it by the 3rd trimester. I always measure all 4 chambers in pts with liver disease because often multiple chambers are enlarged",
        "media": []
      },
      {
        "date": "Thu, 07 Apr 2022 02:23:54 GMT",
        "timestamp": 1649312634.0,
        "text": "1/ As NAFLD becomes the leading cause of end-stage liver disease with the older age of liver transplant recipients we are seeing more cases of elevated PCWP pre-transplant. Pts often have risk factors for diastolic dysfunction but would normally be grade I DD.",
        "media": []
      },
      {
        "date": "Thu, 07 Apr 2022 02:24:26 GMT",
        "timestamp": 1649312666.0,
        "text": "2/ But with high flow coupled with DD and LA stiffening, PCWP goes up. In fact, lack of LA dilation in response to \u2b06\ufe0fCO may be a sign of LA stiffening in ESLD and that\u2019s why smaller LA volumes had worse outcomes. That or pulmonary vascular disease with LA underfilling.\n# All Threads from @HFpEF\n\nChronological order. Threads and tweets deduplicated. Media stored locally.\n\n\n# All Threads from @HFpEF\n\nChronological order. Threads and tweets deduplicated. Media stored locally.",
        "media": []
      }
    ]
  },
  {
    "id": "1511502280770805777",
    "type": "single",
    "date": "2022-03-30",
    "year": 2022,
    "tweet_count": 1,
    "is_pearl": false,
    "categories": [
      "General"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Wed, 30 Mar 2022 18:06:56 GMT",
        "timestamp": 1648678016.0,
        "text": "Naming clinical trials is my main contribution to science... and now GPT-4 has taken that way from me... #GRUMPY: Gpt4 RUined My Pastime, Yikes!",
        "media": []
      }
    ]
  },
  {
    "id": "1468939325178105866",
    "type": "thread",
    "date": "2021-12-09",
    "year": 2021,
    "tweet_count": 4,
    "is_pearl": false,
    "categories": [
      "Tweetorial",
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/fgk10lnxwamf5se.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Thu, 09 Dec 2021 18:58:21 GMT",
        "timestamp": 1639094301.0,
        "text": "1/ P wave is clearly visible before the 2nd QRS complex, so A wave as marked is incorrect. Based on the look of the LA, likely very poor LA function and therefore non-existent A wave. Mid-diastolic wave be an L wave but typically E velocity would be a lot higher.",
        "media": [
          {
            "type": "image",
            "path": "media/images/fgk10lnxwamf5se.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Thu, 09 Dec 2021 19:00:28 GMT",
        "timestamp": 1639094428.0,
        "text": "2/ there is controversy in the literature about genesis of L wave. Need to see M mode through mitral valve to tell if it is truly mid-diastolic transmitral flow vs blood swirling in LV during diastole due to severe restrictive HCM.",
        "media": []
      },
      {
        "date": "Thu, 09 Dec 2021 19:03:30 GMT",
        "timestamp": 1639094610.0,
        "text": "3/ even if it is truly transmitral flow it may not be from elevated LA pressure and severely impaired LV relaxation (typical reason given for L wave). Could be due to delayed pulmonary transit time causing prolonged delivery of blood to LA via pulmonary veins \u27a1\ufe0f L wave.",
        "media": []
      },
      {
        "date": "Thu, 09 Dec 2021 19:11:24 GMT",
        "timestamp": 1639095084.0,
        "text": "Also, I\u2019d love to see the tissue Doppler tracings and M-mode through the mitral valve",
        "media": []
      }
    ]
  },
  {
    "id": "1464594638594052100",
    "type": "thread",
    "date": "2021-11-27",
    "year": 2021,
    "tweet_count": 6,
    "is_pearl": false,
    "categories": [
      "Echo",
      "Diagnosis",
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/ffnhdtox0ao9ilv.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/ffnh0qpwqagtqwd.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/ffniyzkxoa4qurq.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/ffunl1ywqagcwwk.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/ffuoa8_xwaibulq.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/ffuo8rxwuamlkuj.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Sat, 27 Nov 2021 13:59:07 GMT",
        "timestamp": 1638039547.0,
        "text": "A woman in her late 60s with a history of limited cutaneous systemic sclerosis, HTN, DM2, DVT, TIA, hypothyroid, ILD, OSA, and GERD presents to ER with leg swelling. Echo shows the following. What's the diagnosis? (thx @nakhtermd for showing me this case!)",
        "media": [
          {
            "type": "image",
            "path": "media/images/ffnhdtox0ao9ilv.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sat, 27 Nov 2021 13:59:08 GMT",
        "timestamp": 1638039548.0,
        "text": "https://t.co/Afedc2CD8N",
        "media": [
          {
            "type": "image",
            "path": "media/images/ffnh0qpwqagtqwd.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sat, 27 Nov 2021 13:59:09 GMT",
        "timestamp": 1638039549.0,
        "text": "E=95 cm/s, A=44 cm/s, E/A=2.1, DT=151 ms, PV s-wave=52 cm/s, PV d-wave=68 cm/s, e' (lat)=5 cm/s, e' (sep)=4 cm/s, E/e' (lat)=19, E/e'(sep)=24",
        "media": [
          {
            "type": "image",
            "path": "media/images/ffniyzkxoa4qurq.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sun, 28 Nov 2021 22:56:30 GMT",
        "timestamp": 1638158190.0,
        "text": "3 months later, echo was repeated. Speckle-tracking LV longitudinal strain bullseye map now look like this. What's the diagnosis? Hint: it's NOT amyloid :)",
        "media": [
          {
            "type": "image",
            "path": "media/images/ffunl1ywqagcwwk.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sun, 28 Nov 2021 22:58:14 GMT",
        "timestamp": 1638158294.0,
        "text": "By the way, here is the ECG at time of first echo... and  is unchanged 3 months later...",
        "media": [
          {
            "type": "image",
            "path": "media/images/ffuoa8_xwaibulq.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sun, 28 Nov 2021 23:02:47 GMT",
        "timestamp": 1638158567.0,
        "text": "The case of the changing speckle-tracking LV longitudinal strain bullseye map.... what's the diagnosis? See https://t.co/LR4mZMVPUo",
        "media": [
          {
            "type": "image",
            "path": "media/images/ffuo8rxwuamlkuj.jpg",
            "remote": false
          }
        ]
      }
    ]
  },
  {
    "id": "1453752893237080065",
    "type": "thread",
    "date": "2021-10-28",
    "year": 2021,
    "tweet_count": 5,
    "is_pearl": false,
    "categories": [
      "Treatment",
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/fczeoalxeaqcuub.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/fczeqw9xeaupiac.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/fczetnjxiaqyfwf.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/fczevtqxiawibez.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Thu, 28 Oct 2021 15:57:53 GMT",
        "timestamp": 1635451073.0,
        "text": "PRESERVED-HF is now published and online @NatureMedicine. RCT of #SGLT2i vs placebo in n=324 #HFpEF pts, LVEF>45%. Clearly positive trial with no heterogeneity by LVEF. +5.8 improvement in KCCQ and +20.8 meter improvement in 6MWT distance. @MkosiborodMD  https://www.nature.com/articles/s41591-021-01536-x.pdf?error=cookies_not_supported&code=6081e327-bcae-4579-9d2e-63fba07e1573",
        "media": []
      },
      {
        "date": "Thu, 28 Oct 2021 15:58:48 GMT",
        "timestamp": 1635451128.0,
        "text": "https://t.co/LJX7pFn0Qk",
        "media": [
          {
            "type": "image",
            "path": "media/images/fczeoalxeaqcuub.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Thu, 28 Oct 2021 15:58:49 GMT",
        "timestamp": 1635451129.0,
        "text": "https://t.co/60x3dkafwD",
        "media": [
          {
            "type": "image",
            "path": "media/images/fczeqw9xeaupiac.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Thu, 28 Oct 2021 15:58:50 GMT",
        "timestamp": 1635451130.0,
        "text": "https://t.co/4WfxBdoTdM",
        "media": [
          {
            "type": "image",
            "path": "media/images/fczetnjxiaqyfwf.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Thu, 28 Oct 2021 15:58:50 GMT",
        "timestamp": 1635451130.0,
        "text": "https://t.co/6JCAkreEtH",
        "media": [
          {
            "type": "image",
            "path": "media/images/fczevtqxiawibez.jpg",
            "remote": false
          }
        ]
      }
    ]
  },
  {
    "id": "1446459461363699719",
    "type": "single",
    "date": "2021-10-08",
    "year": 2021,
    "tweet_count": 1,
    "is_pearl": false,
    "categories": [
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/fblak2kxsau_zkp.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Fri, 08 Oct 2021 12:56:24 GMT",
        "timestamp": 1633712184.0,
        "text": "83-year-old man with HFpEF, NYHA class III. What does the PW Doppler tracing of the RVOT (below) show and what does it mean?",
        "media": [
          {
            "type": "image",
            "path": "media/images/fblak2kxsau_zkp.jpg",
            "remote": false
          }
        ]
      }
    ]
  },
  {
    "id": "1431740526362079233",
    "type": "single",
    "date": "2021-08-28",
    "year": 2021,
    "tweet_count": 1,
    "is_pearl": false,
    "categories": [
      "Treatment"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Sat, 28 Aug 2021 22:28:13 GMT",
        "timestamp": 1630204093.0,
        "text": "Spiro works in HFpEF and is inexpensive\u2026 in my practice it is first line therapy for volume overloaded HFpEF patients unless contraindicated",
        "media": []
      }
    ]
  },
  {
    "id": "1431282661952270337",
    "type": "thread",
    "date": "2021-08-27",
    "year": 2021,
    "tweet_count": 3,
    "is_pearl": false,
    "categories": [
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/e9zvch5xoaisrg3.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/e9zvhuexsaccudx.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Fri, 27 Aug 2021 15:49:14 GMT",
        "timestamp": 1630093754.0,
        "text": "https://t.co/X3VEiFPLaA",
        "media": [
          {
            "type": "image",
            "path": "media/images/e9zvch5xoaisrg3.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 27 Aug 2021 15:49:15 GMT",
        "timestamp": 1630093755.0,
        "text": "https://t.co/79m2Jud8Vm",
        "media": [
          {
            "type": "image",
            "path": "media/images/e9zvhuexsaccudx.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 27 Aug 2021 15:49:16 GMT",
        "timestamp": 1630093756.0,
        "text": "Despite interaction p=0.21 by LVEF, effect seemed to attenuate at \u2b06\ufe0fLVEF. Await further dissection of the data, but wonder if some patients with LVEF>60% didn't have significant congestion. Will know more once we have DELIVER results and can meta-analyze results across true pEF.",
        "media": []
      }
    ]
  },
  {
    "id": "1443994173384929285",
    "type": "thread",
    "date": "2021-08-27",
    "year": 2021,
    "tweet_count": 3,
    "is_pearl": false,
    "categories": [
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/e9z0tttwuamfvzd.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/e9z2anwxmau7o9x.png",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Fri, 27 Aug 2021 16:17:30 GMT",
        "timestamp": 1630095450.0,
        "text": "Great discussion on interatrial shunt devices going on today at @CSIcongress #CSIvirtual. Lots of devices in this field, and lots more to learn about whether or not these devices can help improve symptoms and outcomes in our patients.",
        "media": [
          {
            "type": "image",
            "path": "media/images/e9z0tttwuamfvzd.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 27 Aug 2021 16:17:30 GMT",
        "timestamp": 1630095450.0,
        "text": "https://t.co/82B8fEHLrM",
        "media": [
          {
            "type": "image",
            "path": "media/images/e9z2anwxmau7o9x.png",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 27 Aug 2021 15:49:16 GMT",
        "timestamp": 1630093756.0,
        "text": "Despite interaction p=0.21 by LVEF, effect seemed to attenuate at \u2b06\ufe0fLVEF. Await further dissection of the data, but wonder if some patients with LVEF>60% didn't have significant congestion. Will know more once we have DELIVER results and can meta-analyze results across true pEF.",
        "media": []
      }
    ]
  },
  {
    "id": "1430874232423174146",
    "type": "thread",
    "date": "2021-08-26",
    "year": 2021,
    "tweet_count": 20,
    "is_pearl": false,
    "categories": [
      "Tweetorial",
      "Hemodynamics",
      "Treatment",
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/e9t7jimxiaawnat.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/e9t7z6cxmak7cs4.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/e9t8bskxmaewrpe.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/e9zdtyaxoaga27i.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/e9zdt66wqayfvl3.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/e9zdu9ewuaqrkky.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/e9zi770xeaaft9_.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "https://pbs.twimg.com/media/E9zmDwYWEAQnjUX.jpg",
        "remote": true
      }
    ],
    "tweets": [
      {
        "date": "Thu, 26 Aug 2021 12:46:16 GMT",
        "timestamp": 1629996376.0,
        "text": "1/ I am eagerly awaiting the EMPEROR-Preserved late-breaking clinical trial results presentation tomorrow @ESCardio #ESCCongress. Based on the press release, it looks like for the first time ever we will have a clearly positive phase 3 trial in #HFpEF. But how positive?",
        "media": []
      },
      {
        "date": "Thu, 26 Aug 2021 12:46:16 GMT",
        "timestamp": 1629996376.0,
        "text": "2/ And does #SGLT2i \u2b07\ufe0fHF hospitalization alone or will we finally have a drug that also \u2b07\ufe0fCV death? Does SGLT2i affect quality of life ? All I know is that after working on #HFpEF intensively over the past 15 years, I am thrilled that our patients will now have a proven therapy.",
        "media": []
      },
      {
        "date": "Thu, 26 Aug 2021 12:46:17 GMT",
        "timestamp": 1629996377.0,
        "text": "3/ Although #SGLT2i is not yet approved for #HFpEF, we can already start using it in our HFpEF patients. How? Obviously we can use it in our type 2 diabetic patients. In our non-diabetics, dapagliflozin is approved by the FDA for use in patients at risk for worsening CKD.",
        "media": []
      },
      {
        "date": "Thu, 26 Aug 2021 12:46:17 GMT",
        "timestamp": 1629996377.0,
        "text": "4/ And I would argue that all HFpEF patients are at risk of worsening CKD! In the Dapa-CKD trial, dapagliflozin reduced the primary outcome (renal + CV outcome) in both diabetics and non-diabetics. https://t.co/FLQKSDm4lq",
        "media": [
          {
            "type": "image",
            "path": "media/images/e9t7jimxiaawnat.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Thu, 26 Aug 2021 12:46:18 GMT",
        "timestamp": 1629996378.0,
        "text": "5/ CKD and albuminuria are markers of adverse outcomes in HFpEF. https://t.co/7iXbQ4cI5Z https://t.co/30CkKrsC7u",
        "media": [
          {
            "type": "image",
            "path": "media/images/e9t7z6cxmak7cs4.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Thu, 26 Aug 2021 12:46:18 GMT",
        "timestamp": 1629996378.0,
        "text": "6/ And we have shown in the studies above that CKD and albuminuria are also associated with adverse cardiac mechanics in HFpEF.",
        "media": [
          {
            "type": "image",
            "path": "media/images/e9t8bskxmaewrpe.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Thu, 26 Aug 2021 13:22:22 GMT",
        "timestamp": 1629998542.0,
        "text": "The male faculty need to be part of this discussion @NMHheartdoc @JavedButler1 @StavrosDrakos @gcfmd @jtheywood @JJheart_doc @HFpEF @jteerlinkmd\n  Did you, my friends, know you agreed to be on a #manel? Please challenge the organizers on their speaker selection.",
        "media": []
      },
      {
        "date": "Thu, 26 Aug 2021 13:27:23 GMT",
        "timestamp": 1629998843.0,
        "text": "I agree 100%. However, as a #HFpEF cardiologist, I find that I often need to actively manage the comorbidities in conjunction with the patient's other doctors, and not simply focus on the HF management. I've found that this approach is essential in improving symptoms and outcomes",
        "media": []
      },
      {
        "date": "Thu, 26 Aug 2021 22:22:45 GMT",
        "timestamp": 1630030965.0,
        "text": "How was HFpEF defined? Why? In every HFpEF trial patients have unique characteristics, yet HFpEF is considered a disease!!!!",
        "media": []
      },
      {
        "date": "Thu, 26 Aug 2021 22:26:16 GMT",
        "timestamp": 1630031176.0,
        "text": "#HFpEF is a syndrome, not a disease. And there are many HFpEF phenotypes. But SGLT2-inhibitors have a good chance to benefit a wide spectrum of patients with the HFpEF syndrome given their pleiotropic effects. EMPEROR-Preserved data will hopefully provide insight.",
        "media": []
      },
      {
        "date": "Thu, 26 Aug 2021 23:24:54 GMT",
        "timestamp": 1630034694.0,
        "text": "Here is a nice review on the topic: https://t.co/nvjFWTZiSx",
        "media": []
      },
      {
        "date": "Fri, 27 Aug 2021 11:03:47 GMT",
        "timestamp": 1630076627.0,
        "text": "Do you follow a protocol for diastolic stress test, Dr Shah? @HFpEF",
        "media": []
      },
      {
        "date": "Fri, 27 Aug 2021 11:57:41 GMT",
        "timestamp": 1630079861.0,
        "text": "There's controversy in the literature about relative importance of total RV afterload vs. PVR vs. diastolic pulm gradient (DPG = PADP-PCWP) in HFpEF. It\u2019s not surprising that metrics of total RV afterload like PAC & PA Ea are the best predictors b/c RV cares about total afterload",
        "media": []
      },
      {
        "date": "Fri, 27 Aug 2021 14:29:20 GMT",
        "timestamp": 1630088960.0,
        "text": "GUIDE-HF results presentation by @LindenfeldJoann at @escardio #ESCCongress... expanding #CardioMEMS to NYHA class II and patients with elevated NTproBNP without HF hospitalization... my take-home is that it is a positive trial given pre-COVID-19 impact analysis",
        "media": [
          {
            "type": "image",
            "path": "media/images/e9zdtyaxoaga27i.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 27 Aug 2021 14:29:22 GMT",
        "timestamp": 1630088962.0,
        "text": "",
        "media": [
          {
            "type": "image",
            "path": "media/images/e9zdt66wqayfvl3.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 27 Aug 2021 14:29:25 GMT",
        "timestamp": 1630088965.0,
        "text": "Seems to work just as well (or better) in HF with LVEF > 40%. Interested to see how patients with HFpEF (LVEF \u2265 50%) did...",
        "media": []
      },
      {
        "date": "Fri, 27 Aug 2021 14:29:27 GMT",
        "timestamp": 1630088967.0,
        "text": "",
        "media": [
          {
            "type": "image",
            "path": "media/images/e9zdu9ewuaqrkky.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 27 Aug 2021 14:53:21 GMT",
        "timestamp": 1630090401.0,
        "text": "#GUIDE-HF results stratified by HFrEF, HFmrEF, and HFpEF, per @TheLancet paper (https://t.co/j2uf4vLWbw). No heterogeneity. P(interaction) = 0.75. HFpEF (LVEF\u226550%, n=492): HR 0.86 (95% CI 0.68-1.08), p=0.20.",
        "media": [
          {
            "type": "image",
            "path": "media/images/e9zi770xeaaft9_.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 27 Aug 2021 14:54:15 GMT",
        "timestamp": 1630090455.0,
        "text": "(Also, there may be an error in the paper, N's for each EF subgroup don't add up and are flipped in the main paper vs. supplementary material forest plot).",
        "media": []
      },
      {
        "date": "Fri, 27 Aug 2021 15:05:51 GMT",
        "timestamp": 1630091151.0,
        "text": "Pre-COVID analysis: Overall (N=1000), primary endpoint: HR 0.81 (95% CI 0.66-1.00), P=0.049. No heterogeneity. P(interaction) = 0.51. HFpEF (LVEF\u226550%): HR 0.70 (95% CI 0.47-1.03), P=0.067.",
        "media": [
          {
            "type": "image",
            "path": "https://pbs.twimg.com/media/E9zmDwYWEAQnjUX.jpg",
            "remote": true
          }
        ]
      }
    ]
  },
  {
    "id": "1402904221752217701",
    "type": "thread",
    "date": "2021-06-18",
    "year": 2021,
    "tweet_count": 4,
    "is_pearl": false,
    "categories": [
      "Tweetorial",
      "Echo",
      "Diagnosis"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Tue, 18 Jun 2024 03:20:37 GMT",
        "timestamp": 1718695237.0,
        "text": "1/ What was her LVOT VTI? If it's truly LA myopathy, I would expect low SV due to LA failure. But if it LVOT VTI is normal or even elevated would think high output HF. Very young to have HFpEF especially with normal BMI. Overt HF + low H2FPEF score = atypical cause of HF.",
        "media": []
      },
      {
        "date": "Tue, 18 Jun 2024 03:23:05 GMT",
        "timestamp": 1718695385.0,
        "text": "2/ I had a case just like this when I first started my #HFpEF program in 2007. Very similar presentation with elevated LA volume but LVOT VTI was high. She ended up having vitamin B1 deficiency and resolved with diuretics and B1 supplementation",
        "media": []
      },
      {
        "date": "Tue, 18 Jun 2024 03:25:27 GMT",
        "timestamp": 1718695527.0,
        "text": "3/ In high output states, the first chamber to dilate is typically the LA. We see it all the time in pregnancy and in end-stage liver disease, for example. LA typically dilates first. LA strain can be abnormal simply because LA is overloaded (\u2b06\ufe0fLAP)",
        "media": []
      },
      {
        "date": "Tue, 18 Jun 2024 03:29:07 GMT",
        "timestamp": 1718695747.0,
        "text": "4/ But her very low a' velocity does suggest an intrinsic LA problem that is primary. I would do a bike stress echo and see what happens to her LA strain, A, and a' with exercise. Also Holter monitor to look for occult AF/AFL and consider genetic testing",
        "media": []
      }
    ]
  },
  {
    "id": "1357175957019381761",
    "type": "thread",
    "date": "2021-02-04",
    "year": 2021,
    "tweet_count": 3,
    "is_pearl": false,
    "categories": [
      "General"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Thu, 04 Feb 2021 03:55:37 GMT",
        "timestamp": 1612428937.0,
        "text": "I was asked to give my talk last November, agreed, and pre-recorded my talk already. Today is the first time I am seeing the meeting agenda. I'm very disappointed that no women were included as speakers. I have emailed the organizers to ask that my presentation be withdrawn.",
        "media": []
      },
      {
        "date": "Thu, 04 Feb 2021 04:11:01 GMT",
        "timestamp": 1612429861.0,
        "text": "Thanks for supporting. Instead of withdrawing your (I\u2019m sure) superb presentation, may want to stipulate that you wish to contribute as long as the faculty is diverse.",
        "media": []
      },
      {
        "date": "Thu, 04 Feb 2021 04:16:09 GMT",
        "timestamp": 1612430169.0,
        "text": "Thanks, that's exactly what I suggested. Reorganize the conference to be more inclusive, and I would be happy to participate. I also learned a valuable lesson: always ask to see the agenda for meetings before agreeing to participate!",
        "media": []
      }
    ]
  },
  {
    "id": "1346264004985909249",
    "type": "thread",
    "date": "2021-02-02",
    "year": 2021,
    "tweet_count": 2,
    "is_pearl": false,
    "categories": [
      "Echo"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Tue, 05 Jan 2021 03:11:56 GMT",
        "timestamp": 1609834316.0,
        "text": "X and Y descents are seen nicely during inspiration which is typical (\u2b06\ufe0fexaggerated during inspiration). During expiration they disappear b/c venous pressure is high so top of wave is higher than where we see pulsations. No Kussmauls sign as far as I can see but CVP is likely \u2b06\ufe0f",
        "media": []
      },
      {
        "date": "Tue, 05 Jan 2021 03:13:03 GMT",
        "timestamp": 1609834383.0,
        "text": "Would love to see echo images of you have them.",
        "media": []
      }
    ]
  },
  {
    "id": "1344646625130635266",
    "type": "thread",
    "date": "2020-12-31",
    "year": 2020,
    "tweet_count": 7,
    "is_pearl": true,
    "categories": [
      "Pearl",
      "Hemodynamics",
      "Treatment",
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/eqkjmcpxeau7j9j.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Thu, 31 Dec 2020 14:08:32 GMT",
        "timestamp": 1609441712.0,
        "text": "#HFpEF pearl of the day: The RV cares about total afterload and not the site of pulmonary vascular dz. That\u2019s why PA compliance (PA pulse pressure/SV) & PA effective elastance (PASP/SV) are better markers of prognosis than PVR or DPG. @RyanTedfordMD. See: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.117.004436",
        "media": []
      },
      {
        "date": "Thu, 31 Dec 2020 14:08:32 GMT",
        "timestamp": 1609441712.0,
        "text": "There's controversy in the literature about relative importance of total RV afterload vs. PVR vs. diastolic pulm gradient (DPG = PADP-PCWP) in HFpEF. It\u2019s not surprising that metrics of total RV afterload like PAC & PA Ea are the best predictors b/c RV cares about total afterload",
        "media": []
      },
      {
        "date": "Thu, 31 Dec 2020 14:08:33 GMT",
        "timestamp": 1609441713.0,
        "text": "In HFpEF, we can \u2b07\ufe0fRV afterload by \u2b07\ufe0fPCWP because doing so will \u2b07\ufe0freflected wave from the distal pulm vasc, and will \u2b07\ufe0faugmented systolic PAP. IASD Rx may help by \u2b07\ufe0fPCWP, \u2b06\ufe0fO2 to PA (with resultant pulm. vasodilation)  and \u2b06\ufe0frecruitment of pulmonary vessels.",
        "media": []
      },
      {
        "date": "Thu, 31 Dec 2020 14:08:33 GMT",
        "timestamp": 1609441713.0,
        "text": "See: https://t.co/xkN0WRQlbz",
        "media": []
      },
      {
        "date": "Thu, 31 Dec 2020 14:08:34 GMT",
        "timestamp": 1609441714.0,
        "text": "Although the RV cares about total afterload, doesn\u2019t mean we shouldn\u2019t pay attention to the DPG. We need to know what components of pulmonary vascular dz are contributing to \u2b06\ufe0fRV afterload (PCWP? intrinsic pulmonary vasculopathy/DPG? central PA stiffening?) and try to treat each.",
        "media": []
      },
      {
        "date": "Thu, 31 Dec 2020 14:08:34 GMT",
        "timestamp": 1609441714.0,
        "text": "Though admittedly Rx of CpcPH (especially \u2b06\ufe0fDPG) is a challenge as described in my earlier tweets. Here is how I conceptualize the different phenotypes of PH in HFpEF, which has implications for treatment:",
        "media": [
          {
            "type": "image",
            "path": "media/images/eqkjmcpxeau7j9j.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Thu, 31 Dec 2020 14:08:35 GMT",
        "timestamp": 1609441715.0,
        "text": "How can we improve PA compliance (central PA stiffening)? Device-based treatment to improve PA compliance may be a possibility. See: https://www.dicardiology.com/content/aria-cv-receives-fda-breakthrough-designation-device-treat-pulmonary-arterial-hypertension",
        "media": []
      }
    ]
  },
  {
    "id": "1344083935517618179",
    "type": "thread",
    "date": "2020-12-30",
    "year": 2020,
    "tweet_count": 2,
    "is_pearl": false,
    "categories": [
      "General"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Wed, 30 Dec 2020 00:52:36 GMT",
        "timestamp": 1609307556.0,
        "text": "Totally agree. In pts w/flash pulmonary edema or rapid onset/offset HF, many have a hx of CAD, so need to rule it out with LHC. Even after revasc, rapid onset HF can occur, assoc. with uncontrolled HTN. Flash pulmonary edema seems much less common in obese/metabolic HF patients.",
        "media": []
      },
      {
        "date": "Wed, 30 Dec 2020 00:53:42 GMT",
        "timestamp": 1609307622.0,
        "text": "Here is a classic paper on this topic by Bill Little, one of the original HFpEF gurus. https://www.sciencedirect.com/science/article/abs/pii/S0002870300077164",
        "media": []
      }
    ]
  },
  {
    "id": "1344310132113551368",
    "type": "thread",
    "date": "2020-12-30",
    "year": 2020,
    "tweet_count": 6,
    "is_pearl": true,
    "categories": [
      "Pearl",
      "Echo",
      "Diagnosis",
      "Video"
    ],
    "media": [
      {
        "type": "video",
        "path": "media/videos/r2c5rm4_mudnfyfl.mp4",
        "remote": false
      },
      {
        "type": "video",
        "path": "media/videos/otii2mfpoxdtljc9.mp4",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Wed, 30 Dec 2020 15:51:26 GMT",
        "timestamp": 1609361486.0,
        "text": "Follow-up to yesterday's #HFpEF pearl of the day: Based on the subcostal echo image of the hepatic vein shown below, what is the most likely diagnosis?",
        "media": []
      },
      {
        "date": "Wed, 30 Dec 2020 15:51:29 GMT",
        "timestamp": 1609361489.0,
        "text": "",
        "media": [
          {
            "type": "video",
            "path": "media/videos/r2c5rm4_mudnfyfl.mp4",
            "remote": false
          }
        ]
      },
      {
        "date": "Wed, 30 Dec 2020 23:23:09 GMT",
        "timestamp": 1609388589.0,
        "text": "This was a case of a pt w/HFpEF on whom I did an echo 15 yrs ago (!) when I was a fellow @UCSFCardiology. Back then we fellows had to do all of the echos on nights and wknds, which was a great experience! There is reflux of saline bubbles \u27a1\ufe0f hepatic vein in systole, c/w severe TR",
        "media": []
      },
      {
        "date": "Wed, 30 Dec 2020 23:23:12 GMT",
        "timestamp": 1609388592.0,
        "text": "Systolic flow reversal in the hepatic veins is equivalent to tall V waves on the CVP tracing. In this pt, bubbles only reflux into the hepatic vein during systole. When she takes a breath in, there is no diastolic reflux of bubbles, arguing against restrictive cardiomyopathy.",
        "media": [
          {
            "type": "video",
            "path": "media/videos/otii2mfpoxdtljc9.mp4",
            "remote": false
          }
        ]
      },
      {
        "date": "Wed, 30 Dec 2020 23:23:12 GMT",
        "timestamp": 1609388592.0,
        "text": "This pt likely had a combo of severe TR + stiff RA. Occasionally we see systolic flow reversal into the hepatic veins in patients with a stiff RA or RV in the absence of severe TR (though some TR is typically present).",
        "media": []
      },
      {
        "date": "Thu, 31 Dec 2020 00:09:20 GMT",
        "timestamp": 1609391360.0,
        "text": "Saline was injected for a bubble study and I saw the bubbles refluxing into the hepatic vein so I captured the image.",
        "media": []
      }
    ]
  },
  {
    "id": "1343647448967901189",
    "type": "thread",
    "date": "2020-12-28",
    "year": 2020,
    "tweet_count": 4,
    "is_pearl": true,
    "categories": [
      "Pearl",
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/eqwkzg6xeaes4rw.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Mon, 28 Dec 2020 19:58:10 GMT",
        "timestamp": 1609203490.0,
        "text": "#HFpEF pearl of the day: LV wall stress (=pressure x radius/wall thickness) varies throughout the cardiac cycle. HFpEF pts = \u2b06\ufe0f aortic stiffness \u27a1\ufe0f \u2b06\ufe0f reflected wave. Typically LV is protected b/c wall stress peaks early in systole, but in HFpEF peaks later \u27a1\ufe0f \u2b06\ufe0fmyocardial damage",
        "media": [
          {
            "type": "image",
            "path": "media/images/eqwkzg6xeaes4rw.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Mon, 28 Dec 2020 19:58:10 GMT",
        "timestamp": 1609203490.0,
        "text": "The image above is what we think happens to the myocardium. @JulioChirinosMd published a seminal paper on time-varying pressure-stress relationships using arterial tonometry + speckle-tracking that allows for non-invasive quantification of pressure-stress: https://t.co/ufarTs9cEg",
        "media": []
      },
      {
        "date": "Mon, 28 Dec 2020 19:58:11 GMT",
        "timestamp": 1609203491.0,
        "text": "Why is this important? \u2b06\ufe0fAo wave reflections = risk factor for HFpEF + comorbidities (e.g., CAD) likely predispose to later shift in peak LV systolic wall stress, right when reflected wave hits the LV = \u2b06\ufe0fmyocardial damage. Rx of Ao stiffness or comorbidities could \u2b07\ufe0fLV dysfxn.",
        "media": []
      },
      {
        "date": "Mon, 28 Dec 2020 19:58:11 GMT",
        "timestamp": 1609203491.0,
        "text": "See also: https://t.co/tNAAYZ9biD",
        "media": []
      }
    ]
  },
  {
    "id": "1333266754252910593",
    "type": "single",
    "date": "2020-12-27",
    "year": 2020,
    "tweet_count": 1,
    "is_pearl": false,
    "categories": [
      "Case Study"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Sun, 27 Dec 2020 18:45:25 GMT",
        "timestamp": 1609112725.0,
        "text": "Answer to yesterday's case: Large unroofed coronary sinus ASD with bidirectional shunting. See yesterday's thread for images and discussion. Many great ideas/guesses were posted. The main lesson is that \"normal\" labs (like upper normal Hgb/Hct) in overt \"HFpEF\" \u27a1\ufe0f expand the DDx!",
        "media": []
      }
    ]
  },
  {
    "id": "1341020477146472451",
    "type": "thread",
    "date": "2020-12-21",
    "year": 2020,
    "tweet_count": 76,
    "is_pearl": true,
    "categories": [
      "Pearl",
      "Tweetorial",
      "Case Study",
      "Echo",
      "Hemodynamics",
      "Treatment",
      "Diagnosis",
      "Video"
    ],
    "media": [
      {
        "type": "video",
        "path": "media/videos/rxlkpm2u6ze8arvs.mp4",
        "remote": false
      },
      {
        "type": "video",
        "path": "media/videos/w0a143r0660javzj.mp4",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/ep16gibxeaifybb.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eqczptdxcaee2cg.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eqcz05axaayba2q.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eqcz9owxmaexfcx.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eqcvowqxuaagywv.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eqixkg1xuae3vbv.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eqixiqkxyaaqrpr.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eqixv-nxuaa_mzh.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eqjb6f7wmayc8_j.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eqjcoykxiaiiiij.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eqjcrccwmaios_n.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eqjchxxxeaehukj.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eqjckgcxmaajjda.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eqjdw9ixuaassf_.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eqjdzerxiaakila.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eqjegjrxiai0qrm.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eqjb3t8xaaalwm-.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eqllcepwmaen-uz.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eqmidqzw8aiciph.jpg",
        "remote": false
      },
      {
        "type": "video",
        "path": "media/videos/gm-svp5eza846l9l.mp4",
        "remote": false
      },
      {
        "type": "video",
        "path": "media/videos/txngb5m0gg-zzgvl.mp4",
        "remote": false
      },
      {
        "type": "video",
        "path": "media/videos/pif9pijhgr5x7oci.mp4",
        "remote": false
      },
      {
        "type": "video",
        "path": "media/videos/sbblgcozdwvcottk.mp4",
        "remote": false
      },
      {
        "type": "video",
        "path": "media/videos/8pmc3c71271p9rgn.mp4",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eqq8pl1xiaiac1m.jpg",
        "remote": false
      },
      {
        "type": "video",
        "path": "media/videos/susfcp4_lkafthto.mp4",
        "remote": false
      },
      {
        "type": "video",
        "path": "media/videos/xympbgclfqbozceu.mp4",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eqrj2k0xmaevkxm.jpg",
        "remote": false
      },
      {
        "type": "video",
        "path": "media/videos/zbj_tdvxbuujn7po.mp4",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Mon, 21 Dec 2020 13:59:31 GMT",
        "timestamp": 1608577171.0,
        "text": "#HFpEF pearl of the day: Eval of filling pressures is critical for HFpEF management. Use entire echo and integrate info for filling pressures assessment: E, E/A, decel time, pulm vein flow, LA volume, LA strain, PASP, PR end-diastolic gradient, IVC, hepatic vein, tricuspid E/e'.",
        "media": []
      },
      {
        "date": "Mon, 21 Dec 2020 13:59:31 GMT",
        "timestamp": 1608577171.0,
        "text": "\u2b06\ufe0fE, \u2b07\ufe0fDT, \u2b06\ufe0fE/A, and D-dominant pulm vein flow (in older pts); \u2b06\ufe0fE/e\u2019, \u2b06\ufe0fLA volume (esp. \u2b06\ufe0fLA min volume), \u2b07\ufe0fLA reservoir strain; \u2b06\ufe0fPASP, \u2b06\ufe0fPREDP gradient (in absence of PAH); \u2b06\ufe0ftricuspid E/e\u2019 > 6, \u2b06\ufe0fsize \u2b07\ufe0fcollapsibility of IVC, hep. vein flow reversal all = \u2b06\ufe0ffilling pressures",
        "media": []
      },
      {
        "date": "Mon, 21 Dec 2020 13:59:31 GMT",
        "timestamp": 1608577171.0,
        "text": "Alternatively, continuous flow by 2D doppler into RA (in RV inflow views) or continuous forward flow on hepatic vein tracing can be helpful signs of normal RA pressure.",
        "media": []
      },
      {
        "date": "Mon, 21 Dec 2020 13:59:48 GMT",
        "timestamp": 1608577188.0,
        "text": "Case: 57 yo man with a hx of non-Hodgkin lymphoma, s/p chest XRT 25 yrs ago, mesothelial cell cancer of parotid requiring extensive head/neck resection, remote DVT presents with SOB, chest pain. Coronary CTA: minimal CAD but ++dilated PA, reported as \"evidence of PH\" on CT report",
        "media": []
      },
      {
        "date": "Mon, 21 Dec 2020 13:59:48 GMT",
        "timestamp": 1608577188.0,
        "text": "Came to see me for possible PH due to HFpEF (LVEF was normal at outside hospital) or PAH. Echo showed diastolic septal flattening:",
        "media": [
          {
            "type": "video",
            "path": "media/videos/rxlkpm2u6ze8arvs.mp4",
            "remote": false
          }
        ]
      },
      {
        "date": "Mon, 21 Dec 2020 13:59:48 GMT",
        "timestamp": 1608577188.0,
        "text": "PSAX view showed brisk caval flow into RA:",
        "media": [
          {
            "type": "video",
            "path": "media/videos/w0a143r0660javzj.mp4",
            "remote": false
          }
        ]
      },
      {
        "date": "Mon, 21 Dec 2020 14:34:26 GMT",
        "timestamp": 1608579266.0,
        "text": "Uptake of PYP in recent infarcts is well established. Prior to development of troponin, this was a very active area of investigation.\nIn calcified infarcts/thrombi, PYP uptake can persist much longer. Using SPECT-CT makes recognition of calcifications much easier.",
        "media": []
      },
      {
        "date": "Mon, 21 Dec 2020 22:12:44 GMT",
        "timestamp": 1608606764.0,
        "text": "More info: cardiac index 5.6 L/min/m2. No exercise was done during RHC. More info on echo: RA and RV dilated. LA normal size. E/A ratio = 0.6. E/e' < 8 (normal LV filling pressures).",
        "media": []
      },
      {
        "date": "Mon, 21 Dec 2020 22:12:50 GMT",
        "timestamp": 1608606770.0,
        "text": "More info: cardiac index 5.6 L/min/m2. No exercise was done during RHC. More info on echo: RA and RV dilated. LA normal size. E/A ratio = 0.6. E/e' < 8 (normal LV filling pressures).",
        "media": []
      },
      {
        "date": "Mon, 21 Dec 2020 22:13:16 GMT",
        "timestamp": 1608606796.0,
        "text": "More info: cardiac index 5.6 L/min/m2. No exercise was done during RHC. More info on echo: RA and RV dilated. LA normal size. E/A ratio = 0.6. E/e' < 8 (normal LV filling pressures).",
        "media": []
      },
      {
        "date": "Tue, 22 Dec 2020 12:50:06 GMT",
        "timestamp": 1608659406.0,
        "text": "Answer: partial anomalous pulmonary vein return (PAPVR). Right upper pulmonary vein (RUPV) \u27a1\ufe0f SVC. Tip-offs were dilated RA/RV with evidence of RV volume overload (diastolic septal flattening) but normal RA pressure and no evidence of left heart overload. Brisk caval flow into RA",
        "media": [
          {
            "type": "image",
            "path": "media/images/ep16gibxeaifybb.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Tue, 22 Dec 2020 12:50:07 GMT",
        "timestamp": 1608659407.0,
        "text": "Initial echo c/w over-circulating only the right heart, with no evidence of left heart overload. AV fistula would have overloaded both L+R heart. ASD typically = biatrial enlargement and also overloads L heart. VSDs found in adults mostly bypass the R heart and don't involve  RA.",
        "media": []
      },
      {
        "date": "Tue, 22 Dec 2020 12:50:07 GMT",
        "timestamp": 1608659407.0,
        "text": "Diastolic septal flattening = RV volume overload. DDx = right heart failure with \u2b06\ufe0fRA pressure, typically in the setting of PAH (due to LV underfilling), severe TR, severe PR, PAPVR. I also often see it in large acute PE due to underfilling of the left heart.",
        "media": []
      },
      {
        "date": "Tue, 22 Dec 2020 12:53:16 GMT",
        "timestamp": 1608659596.0,
        "text": "Answer to yesterday's case: PAPVR causing isolated over-circulation of the right heart (RA/RV), diastolic septal flattening (indicative of RV volume overload) but with normal RA pressure, and dilated PA. https://t.co/sApqP5tnML",
        "media": []
      },
      {
        "date": "Tue, 22 Dec 2020 14:50:11 GMT",
        "timestamp": 1608666611.0,
        "text": "PAPVR was missed on the initial CT at the outside hospital.",
        "media": []
      },
      {
        "date": "Tue, 22 Dec 2020 22:54:45 GMT",
        "timestamp": 1608695685.0,
        "text": "See: https://t.co/oMXIz9RkUi. Comparing PCWP and LVEDP can give insights into LA failure. PCWP is also more predictive of poor outcomes than LVEDP in patients with HFpEF. See: https://t.co/F8nHsoan9z",
        "media": []
      },
      {
        "date": "Tue, 22 Dec 2020 22:54:45 GMT",
        "timestamp": 1608695685.0,
        "text": "In this paper: (https://pmc.ncbi.nlm.nih.gov/articles/PMC6224703/ rheumatic valve dz, AF, and \u2b06\ufe0fLA diameter were predictors of PCWP \"overestimation\" of LVEDP. But these all are assoc. with \u2b07\ufe0fLA compliance which is important for what the pulmonary circulation sees in terms of the load imposed on it.",
        "media": []
      },
      {
        "date": "Tue, 22 Dec 2020 22:54:45 GMT",
        "timestamp": 1608695685.0,
        "text": "These issues also have important implications on how we classify PAH vs. PH due to left heart disease, and underscore the importance of accurate measurement of PCWP in patients with HFpEF and in the evaluation of patients with PH (instead of simply relying on the LVEDP alone).",
        "media": []
      },
      {
        "date": "Wed, 23 Dec 2020 14:26:06 GMT",
        "timestamp": 1608751566.0,
        "text": "This is a great explanation \u2014I\u2019ve believed in this from the moment of learning how to do RHC; here is the follow up should we just start measuring LA pressure directly either retrograde or needle puncture of the septum to clearly identify the load on the pulmonary circulation?",
        "media": []
      },
      {
        "date": "Wed, 23 Dec 2020 22:45:54 GMT",
        "timestamp": 1608781554.0,
        "text": "Although transseptal puncture with LA pressure measurement in the cath lab is experiencing a resurgence due to structural heart therapies, I think accurate PCWP measurement + echo with LA strain measurement is likely sufficient to understand pathophysiology in HFpEF patients.",
        "media": []
      },
      {
        "date": "Wed, 23 Dec 2020 22:51:59 GMT",
        "timestamp": 1608781919.0,
        "text": "Thanks for supporting. Instead of withdrawing your (I\u2019m sure) superb presentation, may want to stipulate that you wish to contribute as long as the faculty is diverse.",
        "media": []
      },
      {
        "date": "Thu, 24 Dec 2020 00:02:54 GMT",
        "timestamp": 1608786174.0,
        "text": "Here you go...",
        "media": [
          {
            "type": "image",
            "path": "media/images/eqczptdxcaee2cg.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Thu, 24 Dec 2020 00:02:10 GMT",
        "timestamp": 1608786130.0,
        "text": "Here you go...",
        "media": [
          {
            "type": "image",
            "path": "media/images/eqcz05axaayba2q.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Thu, 24 Dec 2020 00:04:03 GMT",
        "timestamp": 1608786243.0,
        "text": "Here are some examples of normal and abnormal hepatic vein PW Doppler tracings...",
        "media": [
          {
            "type": "image",
            "path": "media/images/eqcz9owxmaexfcx.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Thu, 24 Dec 2020 00:04:04 GMT",
        "timestamp": 1608786244.0,
        "text": "We also review the issues in detail here: https://www.sciencedirect.com/science/article/pii/S0735109717303431",
        "media": []
      },
      {
        "date": "Thu, 24 Dec 2020 01:01:58 GMT",
        "timestamp": 1608789718.0,
        "text": "I had a case very similar to this 15+ years ago and the underlying diagnosis was inflammatory bowel disease, which is associated with \u2b06\ufe0frisk of thrombosis. I assume the factor VII deficiency was not previously known? It can be assoc w/both bleeding and thrombosis, though venous.",
        "media": []
      },
      {
        "date": "Thu, 24 Dec 2020 01:02:47 GMT",
        "timestamp": 1608789767.0,
        "text": "See: https://t.co/irvmZ1eutj",
        "media": []
      },
      {
        "date": "Thu, 24 Dec 2020 22:41:53 GMT",
        "timestamp": 1608867713.0,
        "text": "#HFpEF pearl fo the day: PH-HFpEF with severe RV failure is difficult to manage and is often assoc w/cardiorenal syndrome with \u2b07\ufe0ftransrenal (MAP-CVP) pressure gradient. I use #CardioMEMS, diurese aggressively, and \u2b06\ufe0fBP to 130s-140s (stop anti-HTN meds, add midodrine).",
        "media": []
      },
      {
        "date": "Thu, 24 Dec 2020 22:41:56 GMT",
        "timestamp": 1608867716.0,
        "text": "\u2b06\ufe0f\u2b06\ufe0fPA pressure is often associated with \u2b06\ufe0fRV ischemia. Unlike LAD and LCx, RCA normally fills in systole and diastole. \u2b06\ufe0f\u2b06\ufe0fPA systolic pressure therefore limits RCA perfusion. So need to maintain adequate systemic BP.",
        "media": []
      },
      {
        "date": "Thu, 24 Dec 2020 22:41:59 GMT",
        "timestamp": 1608867719.0,
        "text": "Maintaining adequate systemic BP also helps to \"stiffen up septum\" to help dysfunctional RV by providing buttress to pump against, and prevents septal bowing into LV which \u2b07\ufe0fLV compliance and filling.",
        "media": [
          {
            "type": "image",
            "path": "media/images/eqcvowqxuaagywv.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Thu, 24 Dec 2020 22:42:02 GMT",
        "timestamp": 1608867722.0,
        "text": "Admittedly mgmt of severe PH-HFpEF with RV failure + cardiorenal syndrome is pretty much a \"data-free\" zone, but I've found the mgmt strategy above to be helpful. PDE5i doesn't seem to work, and we still await SERENADE (ERA) and SOUTHPAW (oral prostacyclin) PH-HFpEF trial results",
        "media": []
      },
      {
        "date": "Fri, 25 Dec 2020 00:30:18 GMT",
        "timestamp": 1608874218.0,
        "text": "Thanks Dr. Shah. How do you titrate preload in these patients in ICU setting? Would you continue diuresis until there is diastolic septal flattening on ECHO?\nAlso, do you factor in CVP in these decisions if there is wide-open TR?",
        "media": []
      },
      {
        "date": "Fri, 25 Dec 2020 01:00:24 GMT",
        "timestamp": 1608876024.0,
        "text": "SOUTHPAW failed to enroll - not sure about SERENADE but other ERA trials have shown signal of harm. What do u think of Guazzi\u2019s PDE5i work - seems to be the only positive data out there. But if significant RV failure I think it is reasonable to treat carefully like PAH and pray.",
        "media": []
      },
      {
        "date": "Fri, 25 Dec 2020 04:36:55 GMT",
        "timestamp": 1608889015.0,
        "text": "#HFpEF pearl of the day: Obesity is a major risk factor for HFpEF, yet we are terrible at treating it. Weight loss is as impt as diuretics in Rx'ing HFpEF successfully. I've advocated for bariatric surgery in my pts for years, but recently have tried GLP1-RAs and ketogenic diet.",
        "media": [
          {
            "type": "image",
            "path": "media/images/eqixkg1xuae3vbv.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sat, 26 Dec 2020 04:36:56 GMT",
        "timestamp": 1608975416.0,
        "text": "Case #1: 66-year-old woman with morbid obesity (BMI 46.3), HTN, OSA, HFpEF. NYHA class 3. Started ketogenic diet program with breathaylzer, and soon became consistently ketotic. 20-lb weight loss over 3 months. NYHA class 2 and on half her baseline diuretic dose.",
        "media": [
          {
            "type": "image",
            "path": "media/images/eqixiqkxyaaqrpr.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sat, 26 Dec 2020 04:36:56 GMT",
        "timestamp": 1608975416.0,
        "text": "Case #2: 68-year-old woman with obesity (BMI 39.5), DM2, HTN, HFpEF, NYHA class 2. Started GLP1-RA, which resulted in significant weight loss, BMI down to 31. NYHA class I and off of all diuretics.",
        "media": [
          {
            "type": "image",
            "path": "media/images/eqixv-nxuaa_mzh.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sat, 26 Dec 2020 05:16:59 GMT",
        "timestamp": 1608977819.0,
        "text": "The second one was medicinal management, which is usually easier (somewhat) to get a patient to comply.. but how did you get the diet compliance on the first one?",
        "media": []
      },
      {
        "date": "Sat, 26 Dec 2020 05:21:47 GMT",
        "timestamp": 1608978107.0,
        "text": "The second one was medicinal management, which is usually easier (somewhat) to get a patient to comply.. but how did you get the diet compliance on the first one?",
        "media": []
      },
      {
        "date": "Sat, 26 Dec 2020 05:27:59 GMT",
        "timestamp": 1608978479.0,
        "text": "Keyto breathalyzer and associated smartphone app. https://t.co/nQJTY4dFxL",
        "media": []
      },
      {
        "date": "Sat, 26 Dec 2020 05:35:00 GMT",
        "timestamp": 1608978900.0,
        "text": "SOUTHPAW failed to complete enrollment, but I'm hoping that we'll still learn what happened in the pts with PH-HFpEF who did enroll. In the past, I use to try PDE5i quite a bit in PH-HFpEF with \u2b06\ufe0fDPG but rarely saw major benefit, c/w the many neutral NO-sGC-PDE5 HFpEF trials.",
        "media": []
      },
      {
        "date": "Sat, 26 Dec 2020 05:41:11 GMT",
        "timestamp": 1608979271.0,
        "text": "I'll reply about the potential role for ERAs in HFpEF in a separate thread.",
        "media": []
      },
      {
        "date": "Sat, 26 Dec 2020 06:06:17 GMT",
        "timestamp": 1608980777.0,
        "text": "1/ Potential role of endothelin and endothelin receptor antagonists (ERAs) in #HFpEF (Note: would not use these drugs outside of trials in HFpEF, but there may be a subset of HFpEF pts that benefit, hopefully we'll learn from the SERENADE trial). I explain the rationale below:",
        "media": []
      },
      {
        "date": "Sat, 26 Dec 2020 06:06:18 GMT",
        "timestamp": 1608980778.0,
        "text": "2/ Endothelin-1 (ET-1) is \u2b06\ufe0f in HFpEF compared to controls and, \u2b06\ufe0fET-1 is associated with \u2b06\ufe0f PA pressure, \u2b06\ufe0f PA stiffness; \u2b07\ufe0faugmentation of CO and RV s' velocity during exercise; and \u2b07\ufe0fpeak VO2 in patients with HFpEF. See: https://t.co/S9keuktivq",
        "media": [
          {
            "type": "image",
            "path": "media/images/eqjb6f7wmayc8_j.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sat, 26 Dec 2020 06:06:19 GMT",
        "timestamp": 1608980779.0,
        "text": "3/ ERAs have been tested in HFrEF and in HFpEF: REACH-1, ENABLE 1 & 2, HEAT, EARTH in HFrEF and 1 RCT with sitaxentan in HFpEF.",
        "media": [
          {
            "type": "image",
            "path": "media/images/eqjcoykxiaiiiij.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sat, 26 Dec 2020 06:06:19 GMT",
        "timestamp": 1608980779.0,
        "text": "4/ First, high-dose bosentan was tried and was stopped early, due to LFTs and fluid retention with rapid up-titration of bosentan. But patients who were able to tolerate bosentan seemed to do better.",
        "media": [
          {
            "type": "image",
            "path": "media/images/eqjcrccwmaios_n.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sat, 26 Dec 2020 06:06:20 GMT",
        "timestamp": 1608980780.0,
        "text": "5/",
        "media": [
          {
            "type": "image",
            "path": "media/images/eqjchxxxeaehukj.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sat, 26 Dec 2020 06:06:21 GMT",
        "timestamp": 1608980781.0,
        "text": "6/",
        "media": [
          {
            "type": "image",
            "path": "media/images/eqjckgcxmaajjda.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sat, 26 Dec 2020 06:06:21 GMT",
        "timestamp": 1608980781.0,
        "text": "7/ Next, standard dose bosentan was tried in the ENABLE-1 & 2 trials in HFrEF. Again, edema happened early in the bosentan-treated patients.",
        "media": []
      },
      {
        "date": "Sat, 26 Dec 2020 06:06:22 GMT",
        "timestamp": 1608980782.0,
        "text": "8/ In the subgroup of patients who had > 2 kg weight gain early in the trial, those randomized to bosentan had \u2b06\ufe0fmortality compared to placebo. Whereas the opposite trend happened in the subgroup with < 2 kg early weight gain.",
        "media": [
          {
            "type": "image",
            "path": "media/images/eqjdw9ixuaassf_.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sat, 26 Dec 2020 06:06:24 GMT",
        "timestamp": 1608980784.0,
        "text": "9/ In addition, patients with signs of right-sided HF at baseline seemed to respond favorably to bosentan.",
        "media": [
          {
            "type": "image",
            "path": "media/images/eqjdzerxiaakila.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sat, 26 Dec 2020 06:06:24 GMT",
        "timestamp": 1608980784.0,
        "text": "10/ These results suggest that in patients with right-sided HF at baseline who do not develop edema in response to bosentan (ERA) may benefit.",
        "media": []
      },
      {
        "date": "Sat, 26 Dec 2020 06:06:25 GMT",
        "timestamp": 1608980785.0,
        "text": "11/ In #HFpEF, sitxasentan was associated with improved exercise treadmill time compared to placebo, but the drug never progressed further because of toxicities (\u2b06\ufe0fLFTs).",
        "media": [
          {
            "type": "image",
            "path": "media/images/eqjegjrxiai0qrm.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sat, 26 Dec 2020 06:06:25 GMT",
        "timestamp": 1608980785.0,
        "text": "12/ In SERENADE (RCT of macitentan in PH-HFpEF), there was a 4-week stabilization phase to make sure pts were not unstable or susceptible to fluid retention, then 5-week run-in period with macitentan. Pts with fluid retention during run-in were excluded prior to randomization.",
        "media": []
      },
      {
        "date": "Sat, 26 Dec 2020 06:08:06 GMT",
        "timestamp": 1608980886.0,
        "text": "HFpEF is a heterogeneous syndrome, and there are major geographical differences in HFpEF. Morbidly obese HFpEF is most common in the US, but increasing elsewhere in the world.",
        "media": []
      },
      {
        "date": "Sat, 26 Dec 2020 06:08:36 GMT",
        "timestamp": 1608980916.0,
        "text": "Visceral adiposity is the major driver of HFpEF pathogenesis and progression. Even pts with HFpEF who do not seem obese often have \u2b06\ufe0f\u2b06\ufe0fvisceral fat which is pro-inflammatory, activates RAAS and sympathetic nervous systems, and results in BNP deficiency, all detrimental to HFpEF.",
        "media": []
      },
      {
        "date": "Sat, 26 Dec 2020 07:38:59 GMT",
        "timestamp": 1608986339.0,
        "text": "Good rationale and important data from the ENABLE trials finally published! Still, same story with macitentan: no signal for efficacy and more fluid retention in the active group of the small RCT MELODY (https://t.co/3xqs6T4Ikp). Respectfully, not sure this is the way forward.",
        "media": [
          {
            "type": "image",
            "path": "media/images/eqjb3t8xaaalwm-.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sat, 26 Dec 2020 10:17:49 GMT",
        "timestamp": 1608995869.0,
        "text": "And why not exercise? It's the best way to keep healthy, to weight loss and reduce inflammation!",
        "media": []
      },
      {
        "date": "Sat, 26 Dec 2020 17:41:21 GMT",
        "timestamp": 1609022481.0,
        "text": "I definitely agree! Exercise is a key part of my treatment algorithm for HFpEF as explained in an early tweet (https://t.co/bnPSNZVRdL). See also: https://t.co/SbiXmr6QQA",
        "media": [
          {
            "type": "image",
            "path": "media/images/eqllcepwmaen-uz.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sat, 26 Dec 2020 17:43:25 GMT",
        "timestamp": 1609022605.0,
        "text": "Agree, important to closely watch lipids on keto diet. Her lipids at 3 months are stable/slightly improved. Baseline: TC 173, TG 123, HDL 51, LDL 97. After 3 mo keto diet: TC 158, TG 117, HDL 50, LDL 85. HbA1c also improved from 6.5% to 5.7% after 3 months on the keto diet.",
        "media": []
      },
      {
        "date": "Sat, 26 Dec 2020 20:16:32 GMT",
        "timestamp": 1609031792.0,
        "text": "#HFpEF pearl of the day: Beware of \u201cnormal\u201d labs in patients with overt HFpEF and volume overload. Just like \u201cnormal\u201d creatinine could be indicative of hemodilution due to fluid overload, hemoglobin and hematocrit at upper limits of normal could be a clue to underlying etiology.",
        "media": []
      },
      {
        "date": "Sat, 26 Dec 2020 20:16:33 GMT",
        "timestamp": 1609031793.0,
        "text": "Here\u2019s an example case: 73 yo man with HTN, AF, PH-HFpEF with MR, TR. Started on sildenafil by primary cardiologist for PH. When I saw him \u2b06\ufe0f\u2b06\ufe0fJVP with +Kussmaul\u2019s sign, BNP 267 pg/ml, creatinine 0.89 mg/dl, hemoglobin 15.6 g/dl, hematocrit 46.9%. Here is his ECG at the time:",
        "media": [
          {
            "type": "image",
            "path": "media/images/eqmidqzw8aiciph.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sat, 26 Dec 2020 20:17:29 GMT",
        "timestamp": 1609031849.0,
        "text": "Echo: LVEF 45%, RV dilated with RV systolic dysfunction, diastolic septal flattening, severe biatrial enlargement, 3+ TR, 3+ MR. Estimated PASP = 70 mmHg . Estimated RAP = 15 mmHg.",
        "media": []
      },
      {
        "date": "Sat, 26 Dec 2020 20:17:35 GMT",
        "timestamp": 1609031855.0,
        "text": "",
        "media": [
          {
            "type": "video",
            "path": "media/videos/gm-svp5eza846l9l.mp4",
            "remote": false
          }
        ]
      },
      {
        "date": "Sat, 26 Dec 2020 20:18:40 GMT",
        "timestamp": 1609031920.0,
        "text": "I diuresed him and hemoglobin went up to 17.7 g/dl, hematocrit up to 52.3%. What\u2019s the diagnosis?",
        "media": []
      },
      {
        "date": "Sun, 27 Dec 2020 02:43:59 GMT",
        "timestamp": 1609055039.0,
        "text": "Some more images from the echo:",
        "media": [
          {
            "type": "video",
            "path": "media/videos/txngb5m0gg-zzgvl.mp4",
            "remote": false
          }
        ]
      },
      {
        "date": "Sun, 27 Dec 2020 02:44:01 GMT",
        "timestamp": 1609055041.0,
        "text": "",
        "media": [
          {
            "type": "video",
            "path": "media/videos/pif9pijhgr5x7oci.mp4",
            "remote": false
          }
        ]
      },
      {
        "date": "Sun, 27 Dec 2020 02:44:04 GMT",
        "timestamp": 1609055044.0,
        "text": "",
        "media": [
          {
            "type": "video",
            "path": "media/videos/sbblgcozdwvcottk.mp4",
            "remote": false
          }
        ]
      },
      {
        "date": "Sun, 27 Dec 2020 18:42:17 GMT",
        "timestamp": 1609112537.0,
        "text": "The patient was not obese. BMI = 23. No evidence of OSA, and normal PFTs, no evidence of lung disease. After 12 lbs of diuresis, RHC showed: RA 6 (with V waves up to 12), RV 32/6, PA 32/16 (mean 21), PCWP 12. CO = 10.4, PVR = ~1.0 WU. PA sat 89% (full sat run not done).",
        "media": []
      },
      {
        "date": "Sun, 27 Dec 2020 18:42:21 GMT",
        "timestamp": 1609112541.0,
        "text": "TEE showed large ASD with unroofed coronary sinus, with bi-directional shunting. He underwent mitral and tricuspid repair (with annuloplasty rings), and pericardial patch repair of unroofed coronary sinus ASD. 6+ years later he continues to do well with NYHA class I symptoms.",
        "media": [
          {
            "type": "video",
            "path": "media/videos/8pmc3c71271p9rgn.mp4",
            "remote": false
          }
        ]
      },
      {
        "date": "Sun, 27 Dec 2020 18:42:22 GMT",
        "timestamp": 1609112542.0,
        "text": "Polycythemia resolved post-operatively, with normal hemoglobin and hematocrit levels. He did not have Eisenmenger syndrome, but R\u27a1\ufe0fL shunting through large unroofed coronary sinus and intermittently from RA\u27a1\ufe0fLA due to stiff RA/RV and possibly eccentric TR jet.",
        "media": [
          {
            "type": "image",
            "path": "media/images/eqq8pl1xiaiac1m.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sun, 27 Dec 2020 18:42:25 GMT",
        "timestamp": 1609112545.0,
        "text": "",
        "media": [
          {
            "type": "video",
            "path": "media/videos/susfcp4_lkafthto.mp4",
            "remote": false
          }
        ]
      },
      {
        "date": "Sun, 27 Dec 2020 18:42:30 GMT",
        "timestamp": 1609112550.0,
        "text": "https://t.co/Y9FAIqCtxo",
        "media": []
      },
      {
        "date": "Sun, 27 Dec 2020 21:41:40 GMT",
        "timestamp": 1609123300.0,
        "text": "#HFpEF pearl fo the day: Kussmaul's sign (\u2b06\ufe0fJVP w/inspiration) is one of the easiest physical signs to elicit (watch neck veins while listening to lungs). If present, it's a clear sign of cardiac pathology (restrictive cardiomyopathy, constriction, severe TR, RV dysfunction).",
        "media": [
          {
            "type": "video",
            "path": "media/videos/xympbgclfqbozceu.mp4",
            "remote": false
          }
        ]
      },
      {
        "date": "Sun, 27 Dec 2020 21:41:41 GMT",
        "timestamp": 1609123301.0,
        "text": "Video modified to protect patient identity (not an alien!). Here's an example of RA pressure tracing from a different patient showing Kussmaul's sign with accentuation of A and V waves in RA pressure tracing during inspiration:",
        "media": [
          {
            "type": "image",
            "path": "media/images/eqrj2k0xmaevkxm.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sun, 27 Dec 2020 21:41:45 GMT",
        "timestamp": 1609123305.0,
        "text": "The patient in the video above had NYHA class III symptoms of dyspnea on exertion with minimal evidence of fluid overload on exam. Cardiac work-up was \"normal\". But looking back at the echo after the physical exam showed Kussmaul's sign revealed the following:",
        "media": []
      },
      {
        "date": "Sun, 27 Dec 2020 21:41:45 GMT",
        "timestamp": 1609123305.0,
        "text": "Although cardiac chamber measurements were \"normal\", it is clear from A4c view that there is significant biatrial enlargement, consistent with restrictive cardiomyopathy. This pt ended up having severe coronary microvascular dysfxn due to diabetes = likely cause of HFpEF.",
        "media": [
          {
            "type": "video",
            "path": "media/videos/zbj_tdvxbuujn7po.mp4",
            "remote": false
          }
        ]
      }
    ]
  },
  {
    "id": "1340064225268543490",
    "type": "thread",
    "date": "2020-12-19",
    "year": 2020,
    "tweet_count": 9,
    "is_pearl": true,
    "categories": [
      "Pearl",
      "Tweetorial",
      "Case Study",
      "Echo",
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/epjco5kwmaao2qz.png",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Fri, 18 Dec 2020 22:39:43 GMT",
        "timestamp": 1608349183.0,
        "text": "#HFpEF pearl of the day: Learn the causes of false-positive Tc-PYP scan for ATTR cardiomyopathy. Always send AL amyloid lab work-up to exclude plasma cell dyscrasia, no matter what the PYP scan shows. Blood pool uptake can be ruled out with SPECT imaging.",
        "media": [
          {
            "type": "image",
            "path": "media/images/epjco5kwmaao2qz.png",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 18 Dec 2020 22:39:43 GMT",
        "timestamp": 1608349183.0,
        "text": "The table above is from a great paper on this topic by @maz_hanna, @Ron_Witteles, @MarthaGrogan1, @frederickruberg, and others. https://t.co/IBjdVhgsPg",
        "media": []
      },
      {
        "date": "Fri, 18 Dec 2020 22:39:43 GMT",
        "timestamp": 1608349183.0,
        "text": "For the 2 cases I showed today: Case #1: False positive PYP scan due to recent MI. Endomyocardial bx showed no amyloid deposition, just interstitial fibrosis. Case #2: False positive PYP scan due to hydroxychloroquine toxicity. Bx: no amyloid, +intense cardiomyocyte vacuolization",
        "media": []
      },
      {
        "date": "Sat, 19 Dec 2020 00:19:20 GMT",
        "timestamp": 1608355160.0,
        "text": "Didn't see LAVI, but suspect grade 2 diastolic dysfunction (E variability, is there Valsalva?). Group II PHTN. Hydroxychloroquine CMP?",
        "media": []
      },
      {
        "date": "Sat, 19 Dec 2020 00:26:06 GMT",
        "timestamp": 1608355566.0,
        "text": "LAVI = 28 ml/m2",
        "media": []
      },
      {
        "date": "Sat, 19 Dec 2020 13:43:04 GMT",
        "timestamp": 1608403384.0,
        "text": "The table above is from a great paper on this topic by @maz_hanna, @Ron_Witteles, @MarthaGrogan1, @frederickruberg, and others. https://t.co/IBjdVhgsPg",
        "media": []
      },
      {
        "date": "Sat, 19 Dec 2020 13:51:09 GMT",
        "timestamp": 1608403869.0,
        "text": "1/ I recently saw a 56 yo pt whose father had rare TTR G67V variant and ATTR-CM. My pt had same G67V variant. +LVH on echo. He also had bicuspid aortic valve w/severe AS. Prealbumin (TTR) level was very low (17.9 mg/dl, normal range 17.0-34.0 mg/dl) indicating ++misfolded TTR.",
        "media": []
      },
      {
        "date": "Sat, 19 Dec 2020 13:51:09 GMT",
        "timestamp": 1608403869.0,
        "text": "2/ PYP H/CL 1.1 and grade 1 uptake. I wondered about false negative PYP. Underwent AVR, and at time of surgery I had surgeon sample LV: No evidence of amyloid deposition. But as we learn more there may be additional TTR variants (besides Phe64Leu) that do not show up on PYP scan.",
        "media": []
      },
      {
        "date": "Sat, 19 Dec 2020 13:58:34 GMT",
        "timestamp": 1608404314.0,
        "text": "Uptake of PYP in recent infarcts is well established. Prior to development of troponin, this was a very active area of investigation.\nIn calcified infarcts/thrombi, PYP uptake can persist much longer. Using SPECT-CT makes recognition of calcifications much easier.",
        "media": []
      }
    ]
  },
  {
    "id": "1339988590248509445",
    "type": "thread",
    "date": "2020-12-18",
    "year": 2020,
    "tweet_count": 6,
    "is_pearl": false,
    "categories": [
      "Case Study",
      "Echo",
      "Video"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/epix8zexcaar5wy.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/epiyafgxuaa5mt1.jpg",
        "remote": false
      },
      {
        "type": "video",
        "path": "media/videos/vd-rgcwkpesjx0d7.mp4",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Fri, 18 Dec 2020 17:39:10 GMT",
        "timestamp": 1608331150.0,
        "text": "Case: 70 yo woman w/paroxysmal AFib, HTN, T2DM hasn\u2019t seen MD in a few years admitted w/acute decompensated HF. ECG with low volts. Echo: LVEF 32%, \u2b06\ufe0fLV wall thickness, & severely \u2b07\ufe0fTDI velocities (s\u2019, e\u2019, and a\u2019 < 5 cm/s at the septum, nearly this low at lateral mitral annulus).",
        "media": [
          {
            "type": "image",
            "path": "media/images/epix8zexcaar5wy.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 18 Dec 2020 17:39:11 GMT",
        "timestamp": 1608331151.0,
        "text": "",
        "media": [
          {
            "type": "image",
            "path": "media/images/epiyafgxuaa5mt1.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 18 Dec 2020 17:39:23 GMT",
        "timestamp": 1608331163.0,
        "text": "",
        "media": [
          {
            "type": "video",
            "path": "media/videos/vd-rgcwkpesjx0d7.mp4",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 18 Dec 2020 17:39:24 GMT",
        "timestamp": 1608331164.0,
        "text": "What would you do next?",
        "media": []
      },
      {
        "date": "Fri, 18 Dec 2020 22:51:49 GMT",
        "timestamp": 1608349909.0,
        "text": "Answer: endomyocardial biopsy. Recent MI was the cause of false positive PYP scan. Given very +PYP uptake, would want to definitively rule out ATTR-CM so biopsy needed. Wall motion was tip-off to exclude MI. CMR would help but would still not answer Q about ATTR-CM definitively.",
        "media": []
      },
      {
        "date": "Fri, 18 Dec 2020 22:51:49 GMT",
        "timestamp": 1608349909.0,
        "text": "DON'T GIVE THIS PATIENT TAFAMIDIS! Need to be vigilant about potential for false positive PYP scans. Perform endomyocardial bx if any doubt. PYP is a great tool, but most published studies done in pts with \u2b06\ufe0fpre-test prob. As we use test more widely, will learn about best uses.",
        "media": []
      }
    ]
  },
  {
    "id": "1339356177466093569",
    "type": "thread",
    "date": "2020-12-17",
    "year": 2020,
    "tweet_count": 2,
    "is_pearl": false,
    "categories": [
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/eput2blu8aik-n3.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Thu, 17 Dec 2020 02:23:53 GMT",
        "timestamp": 1608189833.0,
        "text": "I see it maybe the same as your practice .",
        "media": [
          {
            "type": "image",
            "path": "media/images/eput2blu8aik-n3.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Thu, 17 Dec 2020 02:28:02 GMT",
        "timestamp": 1608190082.0,
        "text": "This is a good protocol and essentially what we do. I would just add LVOT PW Doppler for VTI to evaluate stroke volume response to exercise.",
        "media": []
      }
    ]
  },
  {
    "id": "1339796653709127681",
    "type": "thread",
    "date": "2020-12-16",
    "year": 2020,
    "tweet_count": 2,
    "is_pearl": false,
    "categories": [
      "General"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Fri, 18 Dec 2020 04:56:29 GMT",
        "timestamp": 1608285389.0,
        "text": "This is a case of severe thiamine deficiency causing high output HF (wet beriberi). The pt was on a starvation diet and only eating small amounts of pita and hummus intermittently while training for a marathon. We ruled out anemia, hyperthyroidism, and liver disease.",
        "media": []
      },
      {
        "date": "Fri, 18 Dec 2020 13:58:34 GMT",
        "timestamp": 1608317914.0,
        "text": "Uptake of PYP in recent infarcts is well established. Prior to development of troponin, this was a very active area of investigation.\nIn calcified infarcts/thrombi, PYP uptake can persist much longer. Using SPECT-CT makes recognition of calcifications much easier.",
        "media": []
      }
    ]
  },
  {
    "id": "1338946662321049603",
    "type": "thread",
    "date": "2020-12-15",
    "year": 2020,
    "tweet_count": 10,
    "is_pearl": true,
    "categories": [
      "Pearl",
      "Case Study",
      "Echo",
      "Video"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/eptik-jwmaiovrs.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eptjfqxw4aybkmg.jpg",
        "remote": false
      },
      {
        "type": "video",
        "path": "media/videos/pzyi7zhtnqua5j7q.mp4",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eptkavww8aqtrkr.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eptkfryw8ayv6g8.jpg",
        "remote": false
      },
      {
        "type": "video",
        "path": "media/videos/hkknslztyhtinhbb.mp4",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/epu4-w8xuamkupq.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Tue, 15 Dec 2020 20:38:55 GMT",
        "timestamp": 1608082735.0,
        "text": "#HFpEF pearl of the day: Bike stress echo is very helpful in the evaluation of HFpEF. In 1 test you can diagnose HFpEF (E/e') and evaluate for CAD (WMA), health of the LA (\u0394 LA strain), LV contractile reserve (\u0394 LV strain), dynamic MR, and dynamic LV outflow tract obstruction.",
        "media": []
      },
      {
        "date": "Tue, 15 Dec 2020 20:38:56 GMT",
        "timestamp": 1608082736.0,
        "text": "Here is an example. 72 yo woman w/HFpEF. With just 25W exercise, E velocity goes way up. And a' velocity goes down dramatically, indicative of LA contractile dysfunction and \u2b06\ufe0fLV end-diastolic stiffness.",
        "media": [
          {
            "type": "image",
            "path": "media/images/eptik-jwmaiovrs.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Tue, 15 Dec 2020 20:38:57 GMT",
        "timestamp": 1608082737.0,
        "text": "Here is what happens to LA reservoir strain in the same patient. LA booster strain goes down at 25W of exercise. Conduit strain also goes down. LA reservoir strain = booster + conduit strains therefore also \u2b07\ufe0f.",
        "media": [
          {
            "type": "image",
            "path": "media/images/eptjfqxw4aybkmg.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Tue, 15 Dec 2020 20:38:58 GMT",
        "timestamp": 1608082738.0,
        "text": "Here is another patient with HFpEF who developed significant PAH superimposed (CpcPH) due to systemic sclerosis. Here is baseline echo:",
        "media": [
          {
            "type": "video",
            "path": "media/videos/pzyi7zhtnqua5j7q.mp4",
            "remote": false
          }
        ]
      },
      {
        "date": "Tue, 15 Dec 2020 20:42:01 GMT",
        "timestamp": 1608082921.0,
        "text": "TAPSE increased from 1.8 cm at rest to 2.5 cm at peak stress:",
        "media": [
          {
            "type": "image",
            "path": "media/images/eptkavww8aqtrkr.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Tue, 15 Dec 2020 20:42:02 GMT",
        "timestamp": 1608082922.0,
        "text": "RV s' velocity increased from 13 cm/s to 19 cm/s at peak stress:",
        "media": [
          {
            "type": "image",
            "path": "media/images/eptkfryw8ayv6g8.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Tue, 15 Dec 2020 20:42:03 GMT",
        "timestamp": 1608082923.0,
        "text": "How did this patient's RV systolic function respond to exercise?",
        "media": []
      },
      {
        "date": "Wed, 16 Dec 2020 01:14:10 GMT",
        "timestamp": 1608099250.0,
        "text": "Here is the 2D echo (A4c view) at peak stress:",
        "media": [
          {
            "type": "video",
            "path": "media/videos/hkknslztyhtinhbb.mp4",
            "remote": false
          }
        ]
      },
      {
        "date": "Wed, 16 Dec 2020 02:51:29 GMT",
        "timestamp": 1608105089.0,
        "text": "Answer: RV systolic function \u2b07\ufe0f with exercise. TAPSE and RV s' velocity are unreliable because of tethering effect of the LV, which gets hyperdynamic during exercise, \"pulling\" the RV longitudinally in the absence of \u2b06\ufe0fRV contractility. Translational motion also problematic.",
        "media": [
          {
            "type": "image",
            "path": "media/images/epu4-w8xuamkupq.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Wed, 16 Dec 2020 02:51:29 GMT",
        "timestamp": 1608105089.0,
        "text": "RV free wall strain analysis can be helpful for more subtle cases of RV dysfunction is there is a question about whether RV is augmenting appropriately with exercise.",
        "media": []
      }
    ]
  },
  {
    "id": "1338618719073947649",
    "type": "thread",
    "date": "2020-12-14",
    "year": 2020,
    "tweet_count": 3,
    "is_pearl": true,
    "categories": [
      "Pearl",
      "Echo",
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/epo6tf2weaiaeyn.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Mon, 14 Dec 2020 22:55:47 GMT",
        "timestamp": 1608004547.0,
        "text": "#HFpEF pearl of the day. We often need to \u201cperturb the system\u201d in HFpEF pts to make the Dx or to understand underlying pathophys. When exercise testing is not feasible, even a simple passive leg raise (preload\u2b06\ufe0f) maneuver can be helpful. Just use a wedge pillow under the legs.",
        "media": []
      },
      {
        "date": "Mon, 14 Dec 2020 22:55:50 GMT",
        "timestamp": 1608004550.0,
        "text": "Effect of passive leg raise on LA reservoir strain: also helpful for HFpEF Dx. Normally LA reservoir strain should augment with passive leg raise but in patients with HFpEF it does not, as shown in the example below.",
        "media": [
          {
            "type": "image",
            "path": "media/images/epo6tf2weaiaeyn.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Mon, 14 Dec 2020 23:13:15 GMT",
        "timestamp": 1608005595.0,
        "text": "Change in LVOT VTI in response to passive leg raise can also be helpful. Normally LVOT VTI will go up in response to \u2b06\ufe0fpreload. If it doesn\u2019t, it may be a sign of a problem with the LA (sign of LA myopathy in HFpEF).",
        "media": []
      }
    ]
  },
  {
    "id": "1338161837452439556",
    "type": "thread",
    "date": "2020-12-13",
    "year": 2020,
    "tweet_count": 2,
    "is_pearl": false,
    "categories": [
      "Hemodynamics",
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/epe8b5-xuaawbrc.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Sun, 13 Dec 2020 17:51:58 GMT",
        "timestamp": 1607899918.0,
        "text": "Great point. This is true, especially because \u2b06\ufe0fPCWP results in \u2b06\ufe0freflected wave which can augment PA systolic pressure, thereby raising PA pulse pressure, mPAP, and TPG. Plotting DPG and PCWP vs. CO during exercise may be more helpful to differentiate PVH (IpcPH) vs CpcPH.",
        "media": []
      },
      {
        "date": "Sun, 13 Dec 2020 17:52:33 GMT",
        "timestamp": 1607899953.0,
        "text": "But in my experience most pts with isolated PVH have only a mild increase in mPAP compared to PCWP whereas CpcPH, there can be a marked difference during exercise as shown in the figure I posted.",
        "media": [
          {
            "type": "image",
            "path": "media/images/epe8b5-xuaawbrc.jpg",
            "remote": false
          }
        ]
      }
    ]
  },
  {
    "id": "1337900223026139136",
    "type": "thread",
    "date": "2020-12-12",
    "year": 2020,
    "tweet_count": 3,
    "is_pearl": false,
    "categories": [
      "Treatment",
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/epeyv6fxcambwxh.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/epeyzzaxiaue7gv.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Sun, 13 Dec 2020 00:16:17 GMT",
        "timestamp": 1607836577.0,
        "text": "At rest, HFpEF pts often have \u2b06\ufe0fLV end-systolic elastance (LV systolic stiffness) (Ees) and \u2b06\ufe0feffective arterial elastance (arterial stiffness) (Ea). During exertion, both Ees and Ea go up. But in HFpEF, they are already elevated and can't go up further \u27a1\ufe0f exercise intolerance.",
        "media": [
          {
            "type": "image",
            "path": "media/images/epeyv6fxcambwxh.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sun, 13 Dec 2020 00:16:17 GMT",
        "timestamp": 1607836577.0,
        "text": "",
        "media": [
          {
            "type": "image",
            "path": "media/images/epeyzzaxiaue7gv.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sun, 13 Dec 2020 00:35:47 GMT",
        "timestamp": 1607837747.0,
        "text": "Arterial stiffness is very important in HFpEF pathogenesis. It causes \u2b06\ufe0f\u2b06\ufe0fBP in the volume overloaded state. In the HFpEF pt with \u2b06\ufe0fBP, always make sure euvolemic before \u2b06\ufe0fanti-HTN therapy.",
        "media": []
      }
    ]
  },
  {
    "id": "1337906211145080833",
    "type": "single",
    "date": "2020-12-12",
    "year": 2020,
    "tweet_count": 1,
    "is_pearl": true,
    "categories": [
      "Pearl"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Sat, 12 Dec 2020 23:44:32 GMT",
        "timestamp": 1607834672.0,
        "text": "#HFpEF pearl of the day: A stiff aorta can cause microvascular dysfunction, and both are often present in HFpEF. Stiff aorta = no buffer to pulsatile load = barotrauma to the microcirculation especially in high flow, low impedance organs (brain, kidney).",
        "media": []
      }
    ]
  },
  {
    "id": "1337430899647008770",
    "type": "single",
    "date": "2020-12-11",
    "year": 2020,
    "tweet_count": 1,
    "is_pearl": false,
    "categories": [
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/eo-cmgpwmaadxus.png",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Fri, 11 Dec 2020 16:15:49 GMT",
        "timestamp": 1607721349.0,
        "text": "Go to the conference website (sent in an email to registrants of the meeting). Click on the box that says \"agenda\",  click on the session you're interested in viewing, and then there is a link to the virtual Zoom room.",
        "media": [
          {
            "type": "image",
            "path": "media/images/eo-cmgpwmaadxus.png",
            "remote": false
          }
        ]
      }
    ]
  },
  {
    "id": "1337479871031881728",
    "type": "thread",
    "date": "2020-12-11",
    "year": 2020,
    "tweet_count": 2,
    "is_pearl": true,
    "categories": [
      "Pearl",
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/eo-uortwmai6a1p.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eo-utnkxuacndzw.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Fri, 11 Dec 2020 19:30:25 GMT",
        "timestamp": 1607733025.0,
        "text": "#HFpEF pearl of the day: There are both \"slow\" and \"fast\" mechanisms of congestion in HFpEF patients. The \"fast\" mechanism is mediated by splanchnic vasoconstriction, which also may have implications for cardiorenal syndrome.",
        "media": [
          {
            "type": "image",
            "path": "media/images/eo-uortwmai6a1p.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 11 Dec 2020 19:30:26 GMT",
        "timestamp": 1607733026.0,
        "text": "",
        "media": [
          {
            "type": "image",
            "path": "media/images/eo-utnkxuacndzw.jpg",
            "remote": false
          }
        ]
      }
    ]
  },
  {
    "id": "1337527840431108100",
    "type": "thread",
    "date": "2020-12-11",
    "year": 2020,
    "tweet_count": 9,
    "is_pearl": false,
    "categories": [
      "Case Study",
      "Echo",
      "Hemodynamics",
      "Image"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/eo_an-fw8aemr9w.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eo_aqwrxyaee4ns.jpg",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/epaurajxcaahdmz.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Fri, 11 Dec 2020 22:41:01 GMT",
        "timestamp": 1607744461.0,
        "text": "Case: 64 yo man w/HFpEF, HTN, obesity, CAD, AF s/p ablation, NYHA 3. Invasive hemodynamics shown below. PCWP 11 at rest, \u2b06\ufe0f to 32 with V waves up to 75 with 20W bike exercise. Only 1+ MR at rest/exercise. What caused the severe elevation in PCWP and V waves with minimal exercise?",
        "media": []
      },
      {
        "date": "Fri, 11 Dec 2020 22:41:02 GMT",
        "timestamp": 1607744462.0,
        "text": "",
        "media": [
          {
            "type": "image",
            "path": "media/images/eo_an-fw8aemr9w.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 11 Dec 2020 22:41:03 GMT",
        "timestamp": 1607744463.0,
        "text": "",
        "media": [
          {
            "type": "image",
            "path": "media/images/eo_aqwrxyaee4ns.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Fri, 11 Dec 2020 22:50:57 GMT",
        "timestamp": 1607745057.0,
        "text": "By the way, at the time of his cardiac catheterization, his NTproBNP was only 98 pg/ml.",
        "media": []
      },
      {
        "date": "Sat, 12 Dec 2020 01:06:34 GMT",
        "timestamp": 1607753194.0,
        "text": "This pt had a very stiff LA, possibly due to AF ablation. There was no evidence of pulmonary vein stenosis on CT. He also had significant coronary microvascular dysfunction. But a stiff LA won\u2019t cause big V waves with exercise by itself. Where did all the extra blood come from??",
        "media": []
      },
      {
        "date": "Sat, 12 Dec 2020 04:57:56 GMT",
        "timestamp": 1607767076.0,
        "text": "Answer to today's case: the pt had a very stiff LA, poss. due to AF ablation. But stiff LA alone cannot cause big V waves. Sympathetic activation\u27a1\ufe0fsplanchnic vasoconstriction w/redistribution of volume from gut/liver\u27a1\ufe0flungs/heart with minimal exertion + stiff LA = big V waves.",
        "media": []
      },
      {
        "date": "Sat, 12 Dec 2020 04:57:56 GMT",
        "timestamp": 1607767076.0,
        "text": "This pt also had significant coronary microvascular dysfxn. Exercise\u27a1\ufe0fmyocardial ischemia\u27a1\ufe0fLV diastolic dysfunction\u27a1\ufe0fincreased load on LA. I tried everything to treat him, nothing worked for 7 years. And then he got an IASD as part of the @corviamedical REDUCE LAP-HF I trial.",
        "media": []
      },
      {
        "date": "Sat, 12 Dec 2020 04:57:57 GMT",
        "timestamp": 1607767077.0,
        "text": "Huge improvement in symptoms, now NYHA class I-II.",
        "media": [
          {
            "type": "image",
            "path": "media/images/epaurajxcaahdmz.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Sat, 12 Dec 2020 04:58:58 GMT",
        "timestamp": 1607767138.0,
        "text": "TDI shows that he has almost no atrial contractile (booster) function despite being in normal sinus rhythm. Septal a' velocity ~ 4 cm/s, lateral a' velocity ~ 3 cm/s.",
        "media": []
      }
    ]
  },
  {
    "id": "1336392670479069184",
    "type": "thread",
    "date": "2020-12-10",
    "year": 2020,
    "tweet_count": 3,
    "is_pearl": false,
    "categories": [
      "Video"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/eovq73awmaktt8g.jpg",
        "remote": false
      },
      {
        "type": "video",
        "path": "media/videos/xdt-rh8msnin25me.mp4",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eovq-jzw4ayxkh4.jpg",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Tue, 08 Dec 2020 19:30:16 GMT",
        "timestamp": 1607473816.0,
        "text": "Constriction vs. restriction: remember this basic info when evaluating #HFpEF patients. Also, it's very helpful to be physically present during R/LHC or hepatic vein imaging to look at respiratory maneuvers yourself.",
        "media": [
          {
            "type": "image",
            "path": "media/images/eovq73awmaktt8g.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Tue, 08 Dec 2020 19:30:17 GMT",
        "timestamp": 1607473817.0,
        "text": "",
        "media": [
          {
            "type": "video",
            "path": "media/videos/xdt-rh8msnin25me.mp4",
            "remote": false
          }
        ]
      },
      {
        "date": "Tue, 08 Dec 2020 19:30:17 GMT",
        "timestamp": 1607473817.0,
        "text": "If the pt is in AF or irregular rhythm consider temporary pacing above native HR during simultaneous R/LHC for consistent R-R intervals to look for concordance vs. discordance in RV and LV pressure tracings.",
        "media": [
          {
            "type": "image",
            "path": "media/images/eovq-jzw4ayxkh4.jpg",
            "remote": false
          }
        ]
      }
    ]
  },
  {
    "id": "1336781346820268035",
    "type": "thread",
    "date": "2020-12-09",
    "year": 2020,
    "tweet_count": 7,
    "is_pearl": false,
    "categories": [
      "Case Study",
      "Echo",
      "Hemodynamics",
      "Video"
    ],
    "media": [
      {
        "type": "video",
        "path": "media/videos/9yaotohshwp9wasg.mp4",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eo1fqtcxeaiylxf.jpg",
        "remote": false
      },
      {
        "type": "video",
        "path": "media/videos/xdt-rh8msnin25me.mp4",
        "remote": false
      },
      {
        "type": "video",
        "path": "media/videos/2wcgzack7qxiuqcg.mp4",
        "remote": false
      },
      {
        "type": "video",
        "path": "media/videos/vh6ghnzih3uxhwtg.mp4",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Wed, 09 Dec 2020 21:14:43 GMT",
        "timestamp": 1607566483.0,
        "text": "Case: 74-year-old woman with HTN, obesity (BMI 46 kg/m2) with dyspnea, leg edema, \u2b06\ufe0fJVP, BNP = 28 pg/ml, LVEF 60%. What is the cause of HFpEF and abnormal septal motion?",
        "media": [
          {
            "type": "video",
            "path": "media/videos/9yaotohshwp9wasg.mp4",
            "remote": false
          }
        ]
      },
      {
        "date": "Wed, 09 Dec 2020 22:34:38 GMT",
        "timestamp": 1607571278.0,
        "text": "Answer: Obesity HFpEF phenotype with severe pericardial, epicardial fat over the RV causing pericardial constraint (not constrictive pericarditis--pericardium was normal). See: https://t.co/Sy7krJKTyg",
        "media": [
          {
            "type": "image",
            "path": "media/images/eo1fqtcxeaiylxf.jpg",
            "remote": false
          }
        ]
      },
      {
        "date": "Wed, 09 Dec 2020 22:35:35 GMT",
        "timestamp": 1607571335.0,
        "text": "Invasive hemodynamics: RA 18, PA 44/20 (mean 28), PCWP 20, CO 5.1 L/min.",
        "media": []
      },
      {
        "date": "Wed, 09 Dec 2020 22:35:35 GMT",
        "timestamp": 1607571335.0,
        "text": "",
        "media": [
          {
            "type": "video",
            "path": "media/videos/xdt-rh8msnin25me.mp4",
            "remote": false
          }
        ]
      },
      {
        "date": "Wed, 09 Dec 2020 22:43:04 GMT",
        "timestamp": 1607571784.0,
        "text": "Another case: 61 yo woman with HTN, obesity (BMI 56 kg/m2), OSA presents with HFpEF (LVEF 60-65%). Invasive hemodynamics: RA 18, PA 56/26 (mean 36), PCWP 26, CO 6.7 L/min. A4c (rest and 25W supine bike exercise):",
        "media": [
          {
            "type": "video",
            "path": "media/videos/2wcgzack7qxiuqcg.mp4",
            "remote": false
          }
        ]
      },
      {
        "date": "Wed, 09 Dec 2020 22:43:05 GMT",
        "timestamp": 1607571785.0,
        "text": "",
        "media": [
          {
            "type": "video",
            "path": "media/videos/vh6ghnzih3uxhwtg.mp4",
            "remote": false
          }
        ]
      },
      {
        "date": "Wed, 09 Dec 2020 22:43:06 GMT",
        "timestamp": 1607571786.0,
        "text": "Here the problem was severe chest wall adiposity with minimal pericardia/epicardial fat.",
        "media": []
      }
    ]
  },
  {
    "id": "1336804304116736005",
    "type": "single",
    "date": "2020-12-09",
    "year": 2020,
    "tweet_count": 1,
    "is_pearl": true,
    "categories": [
      "Pearl",
      "Echo"
    ],
    "media": [],
    "tweets": [
      {
        "date": "Wed, 09 Dec 2020 22:45:57 GMT",
        "timestamp": 1607571957.0,
        "text": "#HFpEF pearl of the day: HFpEF pts with severe obesity (BMI >35 kg/m2) can develop a distinct obese HFpEF phenotype caused by plasma volume expansion + pericardial constraint with minimal intrinsic myocardial dysfxn. Due to pericardial/epicardial fat and/or chest wall adiposity.",
        "media": []
      }
    ]
  },
  {
    "id": "1336355614730096645",
    "type": "thread",
    "date": "2020-12-08",
    "year": 2020,
    "tweet_count": 2,
    "is_pearl": true,
    "categories": [
      "Pearl",
      "Case Study",
      "Video"
    ],
    "media": [
      {
        "type": "video",
        "path": "media/videos/kb2_fn9rwnhjgqd0.mp4",
        "remote": false
      },
      {
        "type": "video",
        "path": "media/videos/c0ttxk-4vm2o1j5v.mp4",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Tue, 08 Dec 2020 16:57:23 GMT",
        "timestamp": 1607464643.0,
        "text": "#HFpEF pearl of the day: Evaluation of motion of the interventricular septum can be helpful to determine etiology/pathophys in HFpEF pts. Case: 58 yo man w/SOB, ascites, 2+ LE edema. EF 50%. Initially referred to hepatology for poss. liver failure. What did liver biopsy show?",
        "media": [
          {
            "type": "video",
            "path": "media/videos/kb2_fn9rwnhjgqd0.mp4",
            "remote": false
          }
        ]
      },
      {
        "date": "Tue, 08 Dec 2020 17:03:01 GMT",
        "timestamp": 1607464981.0,
        "text": "",
        "media": [
          {
            "type": "video",
            "path": "media/videos/c0ttxk-4vm2o1j5v.mp4",
            "remote": false
          }
        ]
      }
    ]
  },
  {
    "id": "1335636029966061568",
    "type": "thread",
    "date": "2020-12-06",
    "year": 2020,
    "tweet_count": 17,
    "is_pearl": false,
    "categories": [
      "Tweetorial",
      "Case Study",
      "Echo",
      "Hemodynamics",
      "Video"
    ],
    "media": [
      {
        "type": "image",
        "path": "media/images/eokix3hxiag61os.png",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eoki7n7xiais_td.png",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eokjcndwmaknufw.png",
        "remote": false
      },
      {
        "type": "video",
        "path": "media/videos/b5jby4jsmiax-pcs.mp4",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eolwfotw8ae3xfv.png",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eol0d7kw8aagifg.png",
        "remote": false
      },
      {
        "type": "image",
        "path": "media/images/eol0kqiw8aaxwhj.png",
        "remote": false
      }
    ],
    "tweets": [
      {
        "date": "Sun, 06 Dec 2020 17:23:39 GMT",
        "timestamp": 1607293419.0,
        "text": "Case: 63-year-old woman with long-standing rheumatoid arthritis presents with dyspnea, LE edema, fatigue. Exam JVP 12 cm, 3/6 holosystolic murmur at LSB, 1+ LE edema. LVEF 60%. TR gradient 40 mmHg, RA pressure 15 mmHg. PASP 55 mmHg.",
        "media": []
      },
      {
        "date": "Sun, 06 Dec 2020 17:27:42 GMT",
        "timestamp": 1607293662.0,
        "text": "Mitral inflow: E velocity 62 cm/s, A 35 cm/s, E/A ratio 2.1.",
        "media": [
          {
            "type": "image",
            "path": "media/images/eokix3hxiag61os.png",
            "remote": false
          }
        ]
      },
      {
        "date": "Sun, 06 Dec 2020 17:28:19 GMT",
        "timestamp": 1607293699.0,
        "text": "Septal TDI: Septal e\u2019 5 cm/s",
        "media": [
          {
            "type": "image",
            "path": "media/images/eoki7n7xiais_td.png",
            "remote": false
          }
        ]
      },
      {
        "date": "Sun, 06 Dec 2020 17:28:43 GMT",
        "timestamp": 1607293723.0,
        "text": "Lateral TDI: Lateral e\u2019 7 cm/s",
        "media": [
          {
            "type": "image",
            "path": "media/images/eokjcndwmaknufw.png",
            "remote": false
          }
        ]
      },
      {
        "date": "Sun, 06 Dec 2020 17:29:44 GMT",
        "timestamp": 1607293784.0,
        "text": "Besides diuresis, what would you do next? How would you grade diastolic function? What type of pulmonary hypertension does the patient have?",
        "media": [
          {
            "type": "video",
            "path": "media/videos/b5jby4jsmiax-pcs.mp4",
            "remote": false
          }
        ]
      },
      {
        "date": "Sun, 06 Dec 2020 23:05:27 GMT",
        "timestamp": 1607313927.0,
        "text": "This was her ECG at the time of presentation to my clinic:",
        "media": [
          {
            "type": "image",
            "path": "media/images/eolwfotw8ae3xfv.png",
            "remote": false
          }
        ]
      },
      {
        "date": "Sun, 06 Dec 2020 23:27:06 GMT",
        "timestamp": 1607315226.0,
        "text": "1/ This was one of the first patients I saw in the @NMCardioVasc HFpEF Clinic when I started it in 2007 at @NorthwesternMed . This was before speckle-tracking echo was widely available and before bone scintigraphy for ATTR-CM.",
        "media": []
      },
      {
        "date": "Sun, 06 Dec 2020 23:27:07 GMT",
        "timestamp": 1607315227.0,
        "text": "2/ Diastolic function was reported as \u201cnormal\u201d, so her PCP worked her up for PAH. However, 1 look at the A4c echo and it looks like restrictive cardiomyopathy. Small ventricles, big atria. Normative values are not always helpful.",
        "media": []
      },
      {
        "date": "Sun, 06 Dec 2020 23:27:07 GMT",
        "timestamp": 1607315227.0,
        "text": "3/ Here the atria are clearly big compared to the ventricles. Biventricular hypertrophy is also present, and the motion of the LV myocardium is consistent with restrictive cardiomyopathy.",
        "media": []
      },
      {
        "date": "Sun, 06 Dec 2020 23:27:08 GMT",
        "timestamp": 1607315228.0,
        "text": "4/ Diastolic function is clearly abnormal w/reduced e\u2019 velocities. E/A ratio is almost 2 in a patient with clear HF. At her age, E/A should be closer to 1. So that alone tells us the diastolic fxn is abnormal (grade 2) and this is pulmonary venous HTN.",
        "media": []
      },
      {
        "date": "Sun, 06 Dec 2020 23:27:09 GMT",
        "timestamp": 1607315229.0,
        "text": "5/ I ordered a cardiac MRI and it showed LVEF 66%, concentric LVH (1.5 cm), RVH. Atypical patchy mild LGE in mid-anterolateral and apical inferior segments.",
        "media": []
      },
      {
        "date": "Sun, 06 Dec 2020 23:27:09 GMT",
        "timestamp": 1607315229.0,
        "text": "6/ RHC showed: RA, PA 65/24 (mean 38), PCWP 22, CO 3 L/min with evidence of restrictive physiology with dip-and-pleateau in the RV and LV tracings, which were concordant.",
        "media": []
      },
      {
        "date": "Sun, 06 Dec 2020 23:27:09 GMT",
        "timestamp": 1607315229.0,
        "text": "7/ I went to PubMed and searched \u201crheumatoid arthritis AND restrictive cardiomyopathy\u201d. Case reports of hydroxychloroquine cardiomyopathy came up, so I proceeded with endomyocardial biopsy. H&E showed evidence of intense vacuolization of the cardiomyocytes:",
        "media": [
          {
            "type": "image",
            "path": "media/images/eol0d7kw8aagifg.png",
            "remote": false
          }
        ]
      },
      {
        "date": "Sun, 06 Dec 2020 23:27:10 GMT",
        "timestamp": 1607315230.0,
        "text": "8/ Electron microscopy showed myelin figures characteristic of hydroxychloroquine cardiomyopathy (she had been on hydroxychloroquine for 20+ years for her RA).",
        "media": [
          {
            "type": "image",
            "path": "media/images/eol0kqiw8aaxwhj.png",
            "remote": false
          }
        ]
      },
      {
        "date": "Sun, 06 Dec 2020 23:27:10 GMT",
        "timestamp": 1607315230.0,
        "text": "9/ I stopped the hydroxychloroquine (HCQ) and treated her HF w/diuretics. She went on to develop near-complete blindness from HCQ maculopathy, and HCQ skeletal myopathy. But she went on to live 11 more years despite her significant restrictive cardiomyopathy.",
        "media": []
      },
      {
        "date": "Sun, 06 Dec 2020 23:27:11 GMT",
        "timestamp": 1607315231.0,
        "text": "10/ A good example that diastology guidelines are not perfect. Use the clinical info and 2D echo to help guide assessment of diastology. And don't be afraid to perform endomyocardial biopsy in HFpEF patients!",
        "media": []
      },
      {
        "date": "Sun, 06 Dec 2020 23:27:51 GMT",
        "timestamp": 1607315271.0,
        "text": "Additional notes: AL amyloid work-up was negative. AA amyloid unlikely because cardiac involvement is very rare though possible, another indication for endomyocardial biopsy in this patient.",
        "media": []
      }
    ]
  }
]